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A B S T R A C T
Background
The Global Programme to Eliminate Lymphatic Filariasis recommends mass treatment of albendazole co-administered with the
microfilaricidal (antifilarial) drugs diethylcarbamazine (DEC) or ivermectin; and recommends albendazole alone in areas where loiasis
is endemic.
Objectives
To assess the effects of albendazole alone, and the effects of adding albendazole to DEC or ivermectin, in people and communities with
lymphatic filariasis.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register of Controlled Trials, MED-
LINE (PubMed), Embase (OVID), LILACS (BIREME), and reference lists of included trials. We also searched the World Health
Organization (WHO) International Clinical Trials Registry Platform and ClinicalTrials.gov to identify ongoing trials. We performed
all searches up to 15 January 2018.
Selection criteria
We included randomized controlled trials (RCTs) and cluster-RCTs that compared albendazole to placebo or no placebo, or compared
albendazole combined with a microfilaricidal drug to a microfilaricidal drug alone, given to people known to have lymphatic filariasis or
communities where lymphatic filariasis was known to be endemic. We sought data on measures of transmission potential (microfilariae
(mf) prevalence and density); markers of adult worm infection (antigenaemia prevalence and density, and adult worm prevalence
detected by ultrasound); and data on clinical disease and adverse events.
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Data collection and analysis
At least two review authors independently assessed the trials, evaluated the risks of bias, and extracted data. The main analysis examined
albendazole overall, whether given alone or added to a microfilaricidal drug. We used data collected from all randomized individuals at
time of longest follow-up (up to 12 months) for meta-analysis of outcomes. We evaluated mf density data up to six months and at 12
months follow-up to ensure that we did not miss any subtle temporal effects. We conducted additional analyses for different follow-up
periods and whether trials reported on individuals known to be infected or both infected and uninfected. We analysed dichotomous
data using the risk ratio (RR) with a 95% confidence interval (CI). We could not meta-analyse data on parasite density outcomes
and we summarized them in tables. Where data were missing, we contacted trial authors. We used GRADE to assess the certainty of
evidence.
Main results
We included 13 trials (12 individually-randomized and one small cluster-randomized trial) with 8713 participants in total. No trials
evaluated population-level effects of albendazole in mass drug administration programmes. Seven trials enrolled people with a variety
of inclusion criteria related to filarial infection, and six trials enrolled individuals from endemic areas. Outcomes were reported as end
or change values. Mf and antigen density data were reported using the geometric mean, log mean and arithmetic mean, and reductions
in density were variously calculated. Two trials discounted any increases in mf density in individuals at follow-up by setting any density
increase to zero.
For mf prevalence over two weeks to 12months, albendazole alone or added to another microfilaricidal drugmakes little or no difference
(RR 0.95, 95% CI 0.85 to 1.07; 5027 participants, 12 trials, high-certainty evidence). For mf density there is no trend, with some
trials reporting a greater reduction in mf density with albendazole and others a greater reduction with the control group. For mf density
up to six months and at 12 months, we do not know if albendazole has an effect (one to six months: 1216 participants, 10 trials, very
low-certainty evidence; at 12 months: 1052 participants, 9 trials, very low-certainty evidence).
For antigenaemia prevalence between six to 12 months, albendazole alone or added to another microfilaricidal drug makes little or
no difference (RR 1.04, 95% CI 0.97 to 1.12; 3774 participants, 7 trials, high-certainty evidence). For antigen density over six to 12
months, the trend shows little or no effect of albendazole; but we do not know if albendazole has an effect on antigen density (1374
participants, 5 trials, very low-certainty evidence). For adult worm prevalence detected by ultrasound at 12 months, albendazole added
to a microfilaricidal drug may make little or no difference (RR 1.16, 95% CI 0.72 to 1.86; 165 participants, 3 trials, low-certainty
evidence).
For people reporting adverse events, albendazole makes little or no difference (RR 0.97, 95% CI 0.84 to 1.13; 2894 participants, 6
trials, high-certainty evidence).
We also provide meta-analyses and GRADE tables by drug, as operationally this may be of interest: for albendazole versus placebo
(4 trials, 1870 participants); for albendazole with DEC compared to DEC alone (8 trials, 3405 participants); and albendazole with
ivermectin compared to ivermectin alone (4 trials, 3438 participants).
Authors’ conclusions
There is good evidence that albendazole makes little difference to clearing microfilaraemia or adult filarial worms in the 12 months
post-treatment. This finding is consistent in trials evaluating albendazole alone, or added to DEC or ivermectin. Trials reporting mf
density included small numbers of participants, calculated density data variously, and gave inconsistent results.
The review raises questions over whether albendazole has any important contribution to the elimination of lymphatic filariasis. To
inform policy for areas with loiasis where only albendazole can be used, it may be worth conducting placebo-controlled trials of
albendazole alone.
P L A I N L A N G U A G E S U M M A R Y
Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis
In this Cochrane Review, Cochrane researchers examined the effects of using albendazole alone and albendazole added to antifilarial
drugs to treat infected people and people who live in areas with lymphatic filariasis. After searching for relevant trials up to January
2018, we included 13 randomized controlled trials (RCTs), including one cluster-RCT, with a total of 8713 participants.
2Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Lymphatic filariasis
Lymphatic filariasis, a disease common in tropical and subtropical areas, is spread by mosquitoes and caused by infection with parasitic
filarial worms. After a person is infected from a mosquito bite, the worms grow into adults and mate to produce microfilariae (mf).
The mf circulate in the blood so they can be collected by mosquitoes, and the infection can be spread to another person. Infection can
be diagnosed by checking for the presence of circulating mf (microfilaraemia) or parasite antigens (antigenaemia), or by ultrasound
imaging to detect live adult worms.
The World Health Organization (WHO) recommends mass treatment of entire populations once a year for many years. Treatment
is a two-drug combination of albendazole and a microfilaricidal (antifilarial) drug, either diethycarbamazine (DEC) or ivermectin.
Albendazole alone is recommended for people when DEC or ivermectin can not be used.
What the research says
Albendazole alone or added to a microfilaricidal drug makes little or no difference to mf prevalence over two weeks to 12 months after
treatment (high-certainty evidence), but we do not know if albendazole alone or in combination reduces mf density between one to
six months (very low-certainty evidence) or at 12 months (very low-certainty evidence).
Treatment with albendazole alone or added to a microfilaricidal drug makes little or no difference to antigenaemia prevalence between
six to 12 months (high-certainty evidence). We do not know if albendazole alone or in combination reduces antigen density over six to
12 months (very low-certainty evidence). Albendazole added to a microfilaricidal drug may make little or no difference to adult worm
prevalence detected by ultrasound at 12 months (low-certainty evidence).
When given alone or added to a microfilaricidal drug, albendazole makes little or no difference to the number of people reporting an
adverse event (high-certainty evidence).
Authors’ conclusions
There is good evidence that albendazole, alone or added to DEC or ivermectin, delivers little or no benefit for totally clearing the mf
or the adult worms up to 12 months after treatment. Evidence for an effect of albendazole in reducing the numbers of mf and adult
worms is inconsistent. To inform policy for areas where ivermectin and DEC can not be given, further research could help determine
whether there is any effect of albendazole alone.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Albendazole alone or added to a microfilaricidal drug for lymphatic filariasis
Patient or population: people with lymphatic f ilariasis or communit ies where lymphatic f ilariasis is endemic
Setting: Brazil, Ghana, Hait i, India, Papua New Guinea, Tanzania, and Zanzibar
Intervention: albendazole alone or in combinat ion with a microf ilaricidal drug
Comparison: placebo or a single microf ilaricidal drug
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no treatment
or a single microfilari-
cidal drug
Risk with albendazole
alone or in combination
with a microfilaricidal
drug
Microf ilaraemia (mf )
prevalence
follow-up: range 2
weeks to 12 months
179 per 1000 174 per 1000
(154 to 196)
RR 0.95
(0.85 to 1.07)
5027
(12 RCTs)
⊕⊕⊕⊕
HIGH
Albendazole makes lit -
t le or no dif ference to
mf prevalence.
Mf density
follow-up: range 1
month to 6 months
In the included studies the ef fects of treatment
with albendazole varied. The dif ference between
treatment groups ranged f rom a 81.7% greater
reduct ion with albendazole to 13.6% greater re-
duct ion with a single microf ilaricidal drug.a
- 1216
(10 RCTs)
⊕©©©
VERY LOWb,c,d
Due to risk of bias, incon-
sistency, and imprecision
We do not know if al-
bendazole has an ef fect
on mf density.
Mf density
follow-up: 12 months
In the included studies the ef fects of treatment
with albendazole varied. The dif ference between
treatment groups ranged f rom a 55.5% greater
reduct ion with albendazole to a 15.8% greater
reduct ion with a single microf ilaricidal drug.e
- 1052
(9 RCTs)
⊕©©©
VERY LOWc,f
Due to inconsistency and
imprecision
We do not know if al-
bendazole has an ef fect
on mf density.
Ant igenaemia preva-
lence
follow-up: range 6
months to 12 months
435 per 1000 452 per 1000
(422 to 487)
RR 1.04
(0.97 to 1.12)
3774
(7 RCTs)
⊕⊕⊕⊕
HIGHg
Albendazole makes lit -
t le or no dif ference
to ant igenaemia preva-
lence4
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Antigen density
follow-up: range 6
months to 12 months
In the included studies treatment with albenda-
zole had lit t le or no ef fect on ant igen density.
There was a 1.5%to 17.1%greater reduct ion with
albendazole in all studies except one; this study
reported a 64.4% greater reduct ion in ant igen
density due to a small reduct ion with albenda-
zole (16.9%) but a large increase in the placebo
group.h
- 1374
(5 RCTs)
⊕©©©
VERY LOWi,j,k
Due to risk of bias and im-
precision
We do not know if al-
bendazole has an ef fect
on ant igen density
Adult worm prevalence
detected by ultrasound
follow-up: 12 months
268 per 1000 311 per 1000
(193 to 499)
RR 1.16
(0.72 to 1.86)
165
(3 RCTs)
⊕⊕©©
LOWl,m,n
Due to indirectness and
imprecision
Albendazole may make
lit t le or no dif ference to
adult worm prevalence
detected by ultrasound
Adverse events 184 per 1000 178 per 1000
(155 to 208)
RR 0.97
(0.84 to 1.13)
2894
(6 RCTs)
⊕⊕⊕⊕
HIGHo
Albendazole makes lit -
t le or no dif ference to
adverse events.
* The risk in the intervent ion group (and its 95% CI) is based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95%CI).
Abbreviat ions: CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aEight studies reported geometric means, one study reported log mean, and one study reported the arithmetic mean. An ef fect
of albendazole (P < 0.05) on the geometric mean mf density was reported in three analyses in two studies. No ef fect of
albendazole (P > 0.05) was reported in six studies that used the geometric mean.
bDowngraded by one for risk of bias: we judged the analyt ical methods used by Beach 1999 and Fox 2005 to obtain the change
in density f rom baseline to follow-up to be at high risk of bias.
cDowngraded by one for inconsistency: the direct ion and magnitude of ef fect reported varied in favour of both albendazole
and a microf ilaricidal drug alone. We judged the ef fects of albendazole to be inconsistent.
dDowngraded by two for imprecision: the opt imal information size was met. There was considerable variat ion in the ef fects
of albendazole, ranging f rom a stat ist ically signif icant ef fect of albendazole (P < 0.05) to lit t le no ef fect. Authors reported mf
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density using geometric means, log means, and arithmetic means. We judged that the range of values that the ef fect est imate
might take would likely include a meaningful ef fect and no ef fect.
eSix studies reported geometric means, one study reported the log mean, and two studies reported the arithmetic mean. Five
studies that assessed the geometric mean reported no ef fect was detected in six analyses (P > 0.05).
fDowngraded by two for imprecision: the opt imal information size was met. There was considerable variat ion in the ef fects
of albendazole; ranging f rom est imates with apparent ly large but underpowered ef fects (P > 0.05) to est imates with lit t le or
no ef fect. Authors reported mf density using geometric means, log means, and arithmetic means. Given the dif ferences in
these measures, we are unable to judge the precision of the est imate of ef fect across the studies.
gNot downgraded for risk of bias: most information is f rom studies at low or unclear risk of bias. Four studies had high risk of
bias for attrit ion, but part icipant numbers at follow-up were generally comparable between groups. We judge plausible bias
unlikely to seriously alter the results.
hThree studies reported geometric means, one study reported the log mean, and one study reported the arithmetic mean. Five
analyses in three studies reported no ef fect of albendazole (P > 0.05).
iDowngraded by one for risk of bias: we judged the analyt ical methods used by Fox 2005 to obtain the change in density f rom
baseline to follow-up to be at high risk of bias.
jNot downgraded for inconsistency: lit t le to no benef it of albendazole was seen consistent ly across the studies. We judged
the direct ion and the magnitude of ef fect to be consistent across studies.
kDowngraded by two for imprecision: the opt imal information size was met. Lit t le to no ef fect of albendazole was consistent ly
reported across the studies. All studies that reported a test for dif f erences reported no stat ist ically signif icant ef fect on
geometric mean antigen density (P > 0.05). We judged that the range of values would probably include lit t le or no ef fect
and exclude appreciable benef it or harm, but with no ef fect est imate or measure of precision we judged this to be seriously
imprecise.
lNot downgraded for risk of bias: all studies had unclear risk of bias for random sequence generat ion. The study contribut ing
the most (68.7%) to the ef fect est imate had high risk of bias for attrit ion, but the number of part icipants followed up was
comparable between groups. We judged plausible bias unlikely to seriously alter the results.
mDowngraded by one for indirectness: this outcome was assessed only in men and boys (three studies). Two studies included
adult men only, and one very small study included adults and children. We judged the evidence for this outcome to have
serious indirectness due to the lack of applicability to the wider populat ion of interest.
nDowngraded by one for imprecision: there were insuf f icient events to meet opt imal information size. The 95% CI around the
pooled est imate of ef fect includes both no ef fect and appreciable benef it and harm, using a 25% relat ive risk reduct ion (RRR).
oNot downgraded for risk of bias: for part icipant and personnel blinding, two studies had unclear risk of bias and one study
was at high risk of bias. A large safety study contribut ing the most to the overall ef fect est imate (52.6%) had low risk of bias
for blinding. We judged plausible bias unlikely to seriously alter the results.
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B A C K G R O U N D
Epidemiology
Lymphatic filariasis is a parasitic infection of threadlike filarial
worms and is endemic in 72 countries. Globally, 856 million peo-
ple in 52 countries require preventive chemotherapy to stop the
spread of infection (WHO 2018a). Bancroftian filariasis, caused
by Wuchereria bancrofti, is responsible for over 90% of infections,
and occurs in tropical regions of Asia, Africa, the Pacific islands,
and in parts of the Caribbean and South America (WHO 2016).
Brugian filariasis is less common, with Brugia malayi occurring in
parts of Asia, and Brugia timori in Indonesia (Taylor 2010). The
implications of lymphatic filariasis for individuals and societies
are manifold. Clinical severity and progression of the disease can
lead to chronic health complications and disability, which may be
accompanied by mental health issues and social stigma, while the
resultant reduced productivity causes nearly USD 1.3 billion per
year in economic losses (Conteh 2010).
Filariasis is transmitted by female mosquitoes from several genera,
including Culex,Anopheles,Mansonia, and Aedes (Bockarie 2009).
Themosquito vectors become infectedwhen they take bloodmeals
from people with early stage larvae, which are termedmicrofilariae
(mf). The larvae develop for about 12 to 15 days in the mosquito
to a third-stage infective larvae (L3 larvae) (Scott 2000). When
the mosquito takes a subsequent blood meal, the larvae enter the
skin, migrate to the lymph vessels, and develop into adult worms
(macrofilariae) in the lymph nodes, where male and female worms
pair. Female worms then produce mf, which migrate to the blood
causing microfilaraemia. The time between being infected and
adult worms producing microfilaraemia is estimated to be about
12 months (Mahoney 1971).
Microfilariae move in and out of circulating peripheral blood ac-
cording to a daily cycle. In most species, levels peak during the
night, between 10 pm and 4 am (Simonsen 1997), a time when
mosquito vectors are actively feeding. In the diurnal subperiodic
strain of W bancrofti, found only in the South Pacific region, mf
are continuously circulating but peak during the day (Bockarie
2009).
Diagnosis and clinical features
Historically, filarial infection has been diagnosed by examination
of a blood smear for mf using microscopy. However, even if blood
is taken at night when mf are in the peripheral blood, not all
infections are detected because mf levels are very low in many
people. Adult worms may also be present but not yet producing
mf, or there may be only a single unmated worm in a lymph
node. Antigen-detection assays for W bancrofti circulating filarial
antigen (CFA) became available for field use during the 1990s.
The assays can be used for sensitive diagnosis of infection at any
time of day (Weil 1997), as they indicate the presence of the adult
worm and do not depend on the temporal presence of mf. A point-
of-care rapid diagnostic test for bancroftian filariasis, the Filariasis
Test Strip (FTS), is used by the Global Programme to Eliminate
Lymphatic Filariasis (GPELF) to detect the presence of filarial
antigens (WHO 2015). Parasite antigen levels can be measured
using the Og4C3 Filariasis Ag ELISA, and the circulating antigen
density is thought to be correlated with the numbers of adult W
bancrofti worms (Harnett 1990; Weil 1990). Ultrasound imaging
can demonstrate the presence of live adult worms (Dreyer 1995).
Many people with filariasis are asymptomatic, even when there
are high parasite densities. However, even people without clinical
symptoms often have lymphatic changes, including lymphangiec-
tasia (widening of the lymphatic vessels) and thickening of the
spermatic cord (Addiss 2000;Dreyer 2000), which can be detected
using ultrasound.
People can experience acute inflammatory episodes, including
acute filarial lymphangitis (AFL), believed to be triggered by the
death of the adult worm, and acute dermatolymphangioadenitis
(ADLA), linked with secondary bacterial infection (Dreyer 1999).
An AFL episode presents with lymphangitis that spreads distally
or in a ‘retrograde’ manner along the lymphatic vessel, creating a
palpable ‘cord’ (Addiss 2007). ADLA episodes reportedly may last
up to 16 days and cause malaise, fever, chills, pain, and swelling,
with episodes typically recurring several times a year (Addiss 2007).
Symptoms of ADLA are more severe and occur much more fre-
quently compared toAFL (Dreyer 1999). RecurrentADLAattacks
are a major factor in the progression to chronic lymphoedema.
Clinical symptoms and signs of chronic conditions include hydro-
coele (excess fluid inside the scrotal sac), lymphoedema (swelling
and enlargement of affected areas of the body), and elephantiasis
(long-standing enlargement and swelling of the limbs, scrota, or
breasts associated with skin thickening).
How the filarial worm causes disease is not well understood. The
followinghave beenproposed: adultworms living in anddamaging
lymph vessels; immunological reactions to the presence and death
of filarial worms; secondary infections of affected areas, which con-
tribute significantly to both acute and chronic disease manifesta-
tions; and host genetics (Dreyer 2000; Cuenco 2009). A major
contributor to inflammation is the release of lipoproteins from the
bacterial endosymbiont Wolbachia, which is found within the cells
of filarial worms (Taylor 2001; Turner 2009). Some or all of these
processes may be important in pathogenesis and immunopatho-
genesis (Babu 2012).
Control and elimination
The main strategy used by the GPELF consists of community-
wide mass drug administration (MDA) to entire populations at
risk in order to interrupt transmission of the disease and prevent
morbidity due to infection. Preventive chemotherapy is consid-
ered necessary where the total population in an implementation
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unit (province, district, or smaller unit) of a given country has an
infection prevalence of 1% or higher. Preventive chemotherapy
aims to interrupt transmission by sustainably reducing commu-
nity microfilaraemia below a critical threshold or by completely
clearing the mf (Ottesen 2006).
The GPELF recommends yearly, single-dose, two-drug regimens
(albendazole plus diethylcarbamazine (DEC) or albendazole plus
ivermectin) for at least five years (corresponding to the reproduc-
tive lifespan of the adult worm), with coverage of at least 65% of
the total at-risk population to prevent transmission.More recently,
for special settings theWHO has recommended the use of annual
treatment with the triple-drug therapy of ivermectin, DEC, and
albendazole (termed IDA) rather than two-drug therapy of alben-
dazole and DEC (WHO 2017a). Overall mf prevalence rates are
believed to be relatively stable over time in endemic communities
in the absence of treatment because of reinfection and new adult
worms producing mf (Meyrowitsch 1995).
The transmission assessment survey (TAS) is used to determine
when infection prevalence (estimated from the number of CFA-
positive or antibody-positive cases in children) is below critical cut-
off thresholds and MDA can stop, and also as a surveillance tool
in order to validate elimination (WHO 2011). Palau, Vietnam,
Wallis andFutuna, theRepublic of theMarshall Islands, andTonga
eliminated lymphatic filariasis as a public health problem in 2018
and 2017 (WHO 2017b; WHO 2017c; WHO 2018b), along
with Togo, the first country in sub-Saharan Africa (WHO2017d),
and Egypt, the first country in the Eastern Mediterranean region (
WHO2018c). They join six countries validated as having achieved
elimination in 2016 (WHO 2016), and China and the Republic
of Korea in 2007 and 2008, respectively.
Transmissiondynamicsmay showvariable efficiency depending on
the vector species in the locality; in processes referred to as limita-
tion, facilitation, and proportionality (WHO 2013;Graves 2016).
Higher treatment coverage for longer periods or other strategies
such as vector control may be required in areas where vectors are
responsible for a high proportion of transmission (Burkot 2002;
Pichon 2002). Vector control for lymphatic filariasis can enhance
the impact on transmission during and afterMDA (WHO2013),
and elimination has also been achieved in some areas such as
the Solomon Islands and Australia using vector control methods
(Burkot 2002; Pichon 2002).
In addition to ‘microfilaricidal’ drugs DEC and ivermectin,
‘macrofilaricidal’ drugs that kill the adult worms have also been
shown to be effective. Antibiotics, such as doxycycline, target
the Wolbachia obligate endosymbiont in the parasite, leading to
long-term sterility and a gradual, sustained killing of adult worms
(Taylor 2005; Debrah 2007). Doxycycline is not currently used
in community-based treatment programmes due to the logistics
of longer treatment regimens and contraindications in pregnant
women and children.
DEC and ivermectin
Both ivermectin and DEC rapidly clear mf from the blood and
suppress their reappearance (Stolk 2005;Geary 2010). Reductions
of 90% from pre-treatment mf levels have been seen after a single
dose of DEC or ivermectin, even one year after treatment (Ottesen
1999). Microfilaraemia can therefore be effectively reduced by
DEC or ivermectin (Taylor 2010). However, the limited effects
on adult worm viability cause new mf infections to replace those
whose microfilaraemia subsides (Vanamail 1990; Weil 1999).
DEC has been in use for filariasis for more than 50 years. In
the early years of control the recommended regimen for DEC
was 6 mg/kg daily for 12 days (WHO 1984). Later, clinical and
community trials determined that single doses given at various
intervals − weekly, monthly, twice a year, and annually − were
equally effective (Eberhard 1989; Mataika 1993; Andrade 1995;
Simonsen 1995). There is reasonable evidence from ultrasound
and clinical observations that DEC kills some adult worms after
single doses (Figueredo-Silva 1996; Norões 1997; Addiss 2000).
Ivermectin is used for the treatment and community control of
onchocerciasis (caused by another filarial worm,Onchocerca volvu-
lus). It has also been effective in community control programmes
for lymphatic filariasis (Cartel 1990; Coutinho 1994; Cao 1997).
Ivermectin is used in areas where both onchocerciasis and lym-
phatic filariasis coexist, as DEC can result in eye damage if given to
individuals with onchocerciasis. Ivermectin is not known to have
any macrofilaricidal activity, and ultrasound studies have shown
that adult worms are not killed by ivermectin even at high doses
over a period of six months (Dreyer 1996; Addiss 2000).
In areas of Central and West Africa co-endemic for lymphatic fi-
lariasis and Loa loa, the filarial eye worm causing loiasis, treatment
with ivermectin or DEC can cause serious adverse events (SAEs)
when there are high L loa mf densities (more than 30,000 mf/
mL) (Boussinesq 1997; Gardon 1997). In these areas, albendazole
alone given twice a year with vector control is recommended if
ivermectin has not already been distributed for either onchocercia-
sis or lymphatic filariasis (WHO 2012;WHO 2017a). Ivermectin
can also cause SAEs in people with onchocerciasis and high L loa
densities; however, treatment with ivermectin was recommended
for onchocerciasis meso- and high-endemic areas following one
of three strategies to manage complications, should they occur
(Mectizan Expert Committee 2004). See Table 1.
Adverse effects of antifilarial drugs can be serious (although rarely
fatal) and prevent people from starting or completing treatment.
The most serious appear to be due to a host immunologic reaction
induced by the rapid killing of mf, and associated with the re-
lease of inflammatory Wolbachia lipoproteins (Cross 2001; Turner
2009). Adverse effects include fever, headache, malaise, muscle
pain, and blood in urine. Local effects include localized pain, ten-
der nodules, lymphadenitis (inflammation of the lymph nodes),
and lymphangitis (inflammation of lymph vessels) (Addiss 2000).
8Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Albendazole
Albendazole has been used widely to treat intestinal parasites since
the late 1980s and may have a potential role in lymphatic filari-
asis control (Ottesen 1999). In an early study on albendazole for
lymphatic filariasis, a high (400 mg) dose taken twice a day for 21
days was believed to be macrofilaricidal due to the serious adverse
reactions the authors attributed to adult worm death (Jayakody
1993). A report from an informal consultation organized by the
WHO went on to suggest that repeated high doses of albenda-
zole have a killing or sterilizing effect on W bancrofti adult worms
(CDS/FIL 1998). However, it was unclear whether adding alben-
dazole to either DEC or ivermectin improves cure, prevents fur-
ther transmission, or influences the occurrence of adverse events
(Addiss 2005).
In 2000, a narrative review by Horton 2000 from GlaxoSmithK-
line, which manufactures albendazole, did not demonstrate that
adding albendazole to either drug increased the frequency or
severity of adverse events. GlaxoSmithKline stated that albenda-
zole does not have a role in morbidity management − it will
not treat the symptoms in people already affected by filariasis
(GlaxoSmithKline 2002). A recent trial reported that a significant
proportion of children with W bancrofti infection had their lym-
phatic pathology reversed when given the combination of alben-
dazole and DEC annually (Kar 2017). We therefore include the
effectiveness of albendazole for reducing disease progression and
incidence of new symptoms as a secondary outcome.
The use of albendazole in MDA programmes for lymphatic filar-
iasis is considered to have ‘beyond filariasis’ benefits, as it addi-
tionally addresses ‘polyparasitism’ through treatment of intestinal
helminth infections (Shenoy 2011). However, a narrative review
by Horton 2009 stated “while there is no doubt about the effi-
cacy of albendazole for the treatment of many helminth diseases,
as a single agent it could never be recommended for filariasis”. In
2005, a systematic review concluded “the addition of albendazole
to DEC or ivermectin does not appear to improve the effectiveness
of either drug alone, and therefore may not directly benefit the
transmission elimination aspect of the lymphatic filariasis control
programme” (Tisch 2005). The authors also commented on the
insufficiency of existing data for comparing the efficacy of drug
regimens against bancroftianfilariasis, andhighlighted the need for
more evidence from comparative randomized controlled studies.
Conversely, an expert opinion review that included meta-analyses
and observational data (also published in 2005) concluded that
co-administration of albendazole was more effective in reducing
mf prevalence than one antifilarial drug alone (Gyapong 2005).
Why it is important to do this review
Since theGPELF’s inception, interventions for lymphatic filariasis
have prevented or cured an estimated 97 million cases and obvi-
ated over USD 100 billion in economic losses over the lifetimes
of the beneficiaries (Ramaiah 2014; Turner 2016). The combined
therapy (albendazole with either ivermectin or DEC) has been en-
dorsed for nearly two decades by theWHO and GPELF, as well as
the Global Alliance to Eliminate Lymphatic Filariasis (GAELF),
who currently state that “the combination of albendazole with
either Mectizan® or DEC has been proven to enhance the effi-
cacy of the individual-drug treatments in reducing the numbers of
parasites in the blood” (GAELF 2018). More recently, researchers
have been investigating higher or more frequent dosing with al-
bendazole (De Britto 2015; Kar 2015), as well as the effective-
ness of the single-dose triple therapy IDA (Thomsen 2016; King
2018).
However, despite policy recommending the addition of albenda-
zole to ivermectin or DEC, or albendazole monotherapy in L loa
co-endemic areas, it remains unclear whether its addition is of any
benefit specifically for lymphatic filariasis.
The previous published version of this Cochrane Review con-
cluded that there was not enough evidence on the effectiveness of
the drug albendazole, either alone or in combination with antifi-
larial drugs, for killing or interrupting transmission of the worms
that cause lymphatic filariasis (Addiss 2005). In light of this, we
aimed to summarize the evidence for the effects of albendazole
alone or combined with a microfilaricidal drug for both individual
treatment and transmission control, updating the previous edition
with new methods and including new trials.
O B J E C T I V E S
To assess the effects of albendazole alone, and the effects of adding
albendazole to DEC or ivermectin, in people and communities
with lymphatic filariasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs), including those randomized
by cluster.
Types of participants
• Adults or children with filarial infection defined by the
presence of mf in the blood, filarial antigens in the blood, or
ultrasound detection of adult worms in lymphatic vessels.
• Populations normally resident in endemic communities and
who are eligible for treatment, regardless of microfilaraemia
status.
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Types of interventions
• Albendazole alone versus placebo or no placebo.
• Albendazole plus DEC versus DEC alone (DEC dose and
regimen same in both arms).
• Albendazole plus ivermectin versus ivermectin alone
(ivermectin dose and regimen same in both arms).
Types of outcome measures
Primary outcomes
Measures of transmission potential
• Mf prevalence.
• Mf density (individual or average community density in
community trials).
Secondary outcomes
Markers of adult worm infection
• Antigenaemia prevalence.
• Antigen density.
• Adult worm prevalence (macrofilariae viability detected by
ultrasound).
Clinical disease
• Acute filariasis (fever plus clinical evidence of inflammation
of the lymphatic system, as defined by primary investigators).
• Appearance or disappearance of hydrocoele or
lymphoedema.
• Reduction in size (or severity or grade) of hydrocoele or
lymphoedema.
Adverse events
• Adverse events that prevent daily activities or require
hospitalization.
• Systemic adverse events (e.g. fever, headache, malaise,
myalgia, or haematuria).
• Local adverse events (e.g. localized pain and inflammation,
tender nodules, lymphadenitis, or lymphangitis).
Search methods for identification of studies
Electronic searches
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
We searched the following databases using the search terms and
strategy described in Appendix 1.
• Cochrane Infectious Diseases Group Specialized Register
(up to 15 January 2018).
• MEDLINE (PubMed, 1966 to 15 January 2018).
• Embase (OVID, 1974 to 15 January 2018).
• Cochrane Central Register of Controlled Trials
(CENTRAL) published in the Cochrane Library (Issue 1, 2018).
• Latin American and Caribbean Health Sciences Literature
(LILACS) (BIREME, 1982 to 15 January 2018).
We also searched the WHO International Clinical Trials Registry
Platform (www.who.int/ictrp/search/en/) and ClinicalTrials.gov,
to identify ongoing trials using the terms: filariasis; albendazole;
benzimidazole.
Searching other resources
We checked the reference lists of all included trials to identify
relevant studies.
Data collection and analysis
Selection of studies
Two review authors, Cara Macfarlane (CM) and Shyam Bud-
hathoki (SB), screened titles and abstracts identified from the
search strategy, obtained full-text copies of all potentially relevant
trials and checked each trial report for evidence of multiple pub-
lications from the same data set. CM and SB independently as-
sessed each trial for inclusion using an eligibility form based on the
inclusion criteria and resolved any disagreements through discus-
sion or, where necessary, by consulting a third review author, Paul
Garner (PG).We contacted trial authors when we required further
information. We planned to contact authors of unpublished trials.
We listed excluded studies and the reasons for their exclusion in
the ‘Characteristics of excluded studies’ table, and studies await-
ing classification in the ‘Studies awaiting classification’ table along
with any known details. We illustrated the study selection process
in a PRISMA diagram.
Data extraction and management
Two review authors (CM and SB) independently extracted data on
trial characteristics, includingmethods, participants, interventions
(including dose and treatment frequency), and outcomes using
a pretested data extraction form. We resolved any differences in
data extraction through discussion or by consulting a third review
author (PG). In the case of unclear or missing data, we attempted
to contact the primary investigators for further information. We
recorded the number of participants randomized in each treatment
group and the number of participants that were analysed for each
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outcome of interest, and reported the loss to follow-up in each
group. When data were shown in figures but were not reported in
the article text, we extracted data using WebPlotDigitizer software
(Version 3.12) (Rohatgi 2017).
RCTs that randomized individuals
For dichotomous outcomes, we recorded the number of partici-
pants experiencing the event and the total number of participants
in each treatment group. For continuous outcomes, we aimed to
extract geometric means and confidence intervals (CIs), together
with the numbers of participants in each group. Where these were
not reported, we extracted the summary measure used (geomet-
ric mean, log mean, or arithmetic mean) and standard deviations
(SDs) or CIs where possible, along with the numbers of partic-
ipants in each group. Where change from baseline results were
presented alongside results purely based on the end value, we only
extracted the change from baseline results.
RCTs that randomized clusters
For cluster-RCTs that met the inclusion criteria, we attempted to
extract the cluster unit, the number of clusters in the trial, the
average size of clusters, and the unit of randomization (such as
household). We extracted the statistical methods used to analyse
the trial along with details describing whether these methods ad-
justed for clustering or other covariates. We attempted to extract
the intra-cluster correlation coefficient (ICC) for the cluster-RCT,
as if this was reported we could adjust the analyses.
We aimed to extract the cluster-adjusted results when a cluster-
RCT adjusted for clustering in their analysis. When the trial did
not account for clustering in their analysis, we extracted the same
data as for trials that randomize individuals.
Assessment of risk of bias in included studies
Two review authors (CM and SB) independently assessed the risks
of bias for each included trial using the Cochrane ‘Risk of bias’
tool (Higgins 2011), and resolved differences of opinion through
discussion with Samuel Johnson (SJ) and PG. For RCTs that ran-
domized individuals we assessed six components: sequence genera-
tion; allocation concealment; blinding (of participants, personnel,
and outcome assessors); incomplete outcome data; selective out-
come reporting; and other potential biases. For the cluster-RCT,
we addressed additional components: recruitment bias; baseline
imbalance; loss of clusters; incorrect analysis; and compatibility
with RCTs randomized by individual.
For sequence generation and allocation concealment, we reported
the methods used. For blinding, we described who was blinded
and the blinding method. For incomplete outcome data, we re-
ported the percentage and proportion of participants lost to fol-
low-up. For selective outcome reporting, we stated any discrep-
ancies between the methods used and the results in terms of the
outcomes measured or the outcomes reported. For other biases,
we described any other trial features that could have affected the
trial result (for example, if the trial was stopped early).
We categorized our ‘Risk of bias’ judgements as either ‘low’, ‘high’,
or ‘unclear’. We displayed the results in ‘Risk of bias’ tables, a ‘Risk
of bias’ summary, and a ‘Risk of bias’ graph.
Measures of treatment effect
We used the risk ratio (RR) to compare the treatment and control
groups for dichotomous outcomes, and presented the treatment
effects with 95% CIs.
For continuous data summarized using geometric means, we
planned to report the geometric mean ratios. Due to the variabil-
ity in the summary measures reported and the lack of reporting
of CIs or measures of variance in the trials, we could not synthe-
size data to obtain pooled treatment effects.We report continuous
outcomes in ‘Additional tables’, and we compare the difference in
the intervention and the control groups’ percentage reductions in
parasitaemia from baseline.
Unit of analysis issues
For a particular cluster-RCT when the analyses had not been ad-
justed for clustering, we planned to try and adjust the results
for clustering by estimating the design effect calculated as 1+(m-
1)*ICC, where m is the average cluster size and ICC is the ICC.
When the true ICC was unknown, we planned to estimate it from
other included cluster-RCTs. As we were unable to estimate the
ICC due to the inclusion of a single cluster-RCT, we presented
the trial authors’ unadjusted data in Appendix 2.
Dealing with missing data
We aimed to conduct a complete-case analysis in this review, such
that all participants with a recorded outcome were included in
the analysis. When necessary, we made extensive efforts to obtain
clarification over aspects of the parasite density data and to obtain
the original data from the trial authors.
Assessment of heterogeneity
We assessed statistical heterogeneity using Chi2 and I2 statistics
(Higgins 2003), and judged any heterogeneity using values of I2
greater than 50% and a Chi2 P value of 0.10 or less to indicate
moderate to substantial statistical heterogeneity (Deeks 2017).
Assessment of reporting biases
We planned to assess the possibility of publication bias by exam-
ining funnel plots for asymmetry, but there were too few trials.
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Data synthesis
One review author (CM) analysed the data using ReviewManager
5 (Review Manager 2014). The main analysis examined albenda-
zole alone or added to a microfilaricidal drug. We sought to iden-
tify evidence of an overall effect of albendazole; in the presence of
high heterogeneity of effects between albendazole alone or added
to either of the microfilaricidal drugs, we would then proceed to
analysis of individual comparisons to see if this explained the het-
erogeneity. However, no such inconsistency was apparent. Never-
theless, we included additional comparisons of albendazole alone
or in combination versus the background drug, be that placebo,
DEC, or ivermectin. We provide this to summarize the reliable
evidence for policy-makers interested in the effectiveness of alben-
dazole regimens for global lymphatic filariasis programmes.
We directly compared treatments using pairwise comparisons.
Some trials randomized infected and uninfected individuals, but
only analysed subgroups of participants who were infected at base-
line. The primary analysis for each outcome included the num-
ber of individuals randomized as the denominator, where possible.
When a trial reported data at multiple time points we included
data collected at the longest follow-up time up to 12 months in
the analysis. The exception to this was data for mf density, which
we analysed by longest follow-up time up to six months and at
12 months to seek evidence of any temporally-dependent effects.
Within the individual drug comparator groups (e.g. albendazole
versus placebo), we also conducted meta-analyses for different fol-
low-up time points, and included data from subgroups of individ-
uals known to be infected or participants who were both infected
and uninfected.
We planned to combine RCTs that randomized individuals and
cluster-RCTs that adjusted for clustering using meta-analysis.
When a cluster-RCT did not adjust for clustering and could not
be combined with RCTs, we reported the results of the cluster-
RCT in an appendix. We used a fixed-effect meta-analysis when
the assessments of heterogeneity did not reveal heterogeneity. In
the presence of statistical heterogeneity we used random-effects
meta-analysis.
For continuous data, we presented data that could not be meta-
analysed in ‘Additional tables’ and reported on these in each sec-
tion under the relevant outcome heading. For the parasite density
data, we examined the summary measure used (geometric, log,
or arithmetic mean), the methods that were used to estimate this
and the change in density post-treatment, and whether the anal-
ysis included the whole population or only infected participants.
We sought approaches to allow meta-analysis of the density data,
but this was not possible due to the variability in the summary
measures reported and the lack of reporting of CIs or measures of
variance. We were also unable to calculate measures of treatment
effect for individual studies, due to the lack of reported measures
of variances or CIs. We therefore reported on the trial authors’
statistical tests of significance.
Where trial authors provided geometric or log estimates of percent-
age reduction for parasite density outcomes (as an average across
participants), we took the estimated percentage reduction in the
intervention and the estimated percentage reduction in the con-
trol and calculated the percentage difference in density reduction
between intervention and control. Whilst we could not conduct
meta-analyses to assess the treatment effect, it gave a measure of
the direction of the possible effect.
Certainty of the evidence
We assessed the certainty of the evidence for each important
outcome using the GRADE approach (Schünemann 2013). All
review authors participated in the GRADE assessment through
several meetings. For the main outcomes in each comparison,
we used GRADE profiler to assess five domains: risk of bias;
inconsistency; indirectness; imprecision; and publication bias
(GRADEpro 2015).
We assessed the overall certainty of the evidence using four cat-
egories (high, moderate, low, or very low). The baseline for each
outcome was set as high-certainty evidence, as all studies were
RCTs. Each GRADE domain could be downgraded by one or two
levels if we judged it to have serious or very serious concerns, and
we detailed the justification for downgrading in footnotes.
We displayed the GRADE rating of the certainty of evidence and
justification for downgrading in the ‘Summary of findings’ tables.
‘Summary of findings’ tables
We interpreted results using ‘Summary of findings’ tables, which
provide key information about the certainty of the evidence for
the included trials in the comparison, the magnitude of effect of
the interventions examined, and the sum of available data on the
main outcomes. Using GRADE profiler (GRADEpro 2015), we
imported data from Review Manager 5 (Review Manager 2014).
We present the main outcomes for the review in the ‘Summary of
findings’ tables. When there was no pooled effect estimate for an
outcome, we presented a narrative synthesis of quantitative data.
Subgroup analysis and investigation of heterogeneity
In the presence of statistically significant heterogeneity, we planned
to explore the following potential sources of heterogeneity using
subgroup analyses: drug dose (comparing regimens where there
are significant variations in drug dose), participant age (children
only, adults only, or whole populations), and length of follow-
up. We conducted subgroup analyses for drug dose and length of
follow-up only, as this appeared to explain the heterogeneity.
Sensitivity analysis
We carried out sensitivity analyses including only those trials with
a low risk of bias for allocation concealment.
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R E S U L T S
Description of studies
Results of the search
See PRISMA flow diagram (Figure 1).
Figure 1. Study flow diagram.
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We included 13 trials (8713 participants), reported in 18 arti-
cles (see Characteristics of included studies). In this Cochrane Re-
view update, we dropped two comparisons (albendazole versus
DEC and albendazole versus ivermectin), so we re-screened all
included, excluded, and ongoing studies from the last published
version (Addiss 2005), in addition to 149 records identified from
the update search. We were unable to locate one record cited in
the previous version of this review, which was a two-year follow-
up to Pani 2002.
We excluded 15 studies (reported in 20 records) at full-text screen-
ing stage (see Characteristics of excluded studies). One study we
excluded that was listed in a trial register (NCT01975441) pub-
lished the full-text article after we conducted the search in 15 Jan-
uary 2018 (King 2018). One trial, Purkait 2017, is awaiting classi-
fication (see Characteristics of studies awaiting classification). We
excluded one trial included in the previous published review, as
it no longer meets the inclusion criteria due to the removal of a
comparison (albendazole versus DEC) (Jayakody 1993).
Included studies
Location
The included trials were undertaken in eight different countries:
India (Pani 2002; Kshirsagar 2004; Gayen 2013; De Britto 2015),
Haiti (Beach 1999; Fox 2005), Brazil (Dreyer 2006; Rizzo 2007),
Papua New Guinea (Bockarie 2007), Zanzibar (Dahoma 2000),
Ghana (Dunyo 2000), Tanzania (Simonsen 2004), and Kenya
(Wamae 2011). All trials were conducted in endemic regions.
Participants
Three trials were school-based and recruited children and adoles-
cents (5 to 18 years old) from school populations (Beach 1999;
Simonsen 2004; Fox 2005); five trials were conducted in commu-
nity settings and recruited adults and children (Dahoma 2000;
Dunyo 2000; Kshirsagar 2004; Bockarie 2007; Wamae 2011).
Three studies were hospital-based and recruited only children and
adolescents (9 to 19 years of age) (Rizzo 2007), only adult men
(Dreyer 2006), or adults and children (Pani 2002). Two trials re-
cruited mf-positive adults from endemic villages (Gayen 2013; De
Britto 2015).
Seven trials enrolled people with a variety of inclusion criteria
related to filarial infection; four only enrolled individuals who
were mf-positive (Pani 2002; Rizzo 2007; Gayen 2013; De Britto
2015); Dreyer 2006 enrolled individuals with detectable filaria
dance sign (FDS); Dahoma 2000 enrolled individuals who had
either microfilaraemia or who were amicrofilaraemic with clini-
cal disease; and Wamae 2011 enrolled individuals if one or more
members of a household were microfilaraemic.
Six trials enrolled individuals irrespective of their infection status
at baseline (Beach 1999; Dunyo 2000; Kshirsagar 2004; Simonsen
2004; Fox 2005; Bockarie 2007). Kshirsagar 2004 enrolled 1403
participants for a safety study and included 103 men in a separate
analysis of efficacy at 3, 6, and 12 months follow-up. Forty-three
of the 103 participants in the smaller efficacy analysis weremf-pos-
itive, 30 had clinical disease, and 30 were mf-negative and asymp-
tomatic. For subsequent assessments at 12, 24, and 36 months
follow-up, men and women from the safety study who were mf-
positive at baseline were also included (155 participants).
Intervention
Four trials assessed albendazole alone versus placebo (Beach 1999;
Dunyo 2000; Fox 2005; Gayen 2013), eight trials assessed al-
bendazole plus DEC versus DEC alone (Pani 2002; Kshirsagar
2004; Fox 2005;Dreyer 2006, Bockarie 2007;Rizzo 2007;Wamae
2011; De Britto 2015) and four trials assessed albendazole plus
ivermectin versus ivermectin alone (Beach 1999; Dahoma 2000;
Dunyo 2000; Simonsen 2004).
Twelve trials used the same albendazole dose (400 mg) (Beach
1999; Dunyo 2000; Pani 2002; Kshirsagar 2004; Simonsen 2004;
Fox 2005;Dreyer 2006; Bockarie 2007;Rizzo 2007;Wamae 2011;
Gayen 2013; De Britto 2015), and Dahoma 2000 did not report
the dose. Drug dose information for Dahoma 2000 appeared to be
reported in the appendices, which were not included in our copy
of the thesis. We contacted the author of Dahoma 2000 and the
librarywhere the thesiswas deposited to obtain the appendices, but
received no response. As albendazole is usually given as a standard
400mg single dose and therewas no indication that a non-standard
dosewas used,we included this trial. In the four placebo-controlled
trials, Dunyo 2000 and Gayen 2013 described tablets as identical
ormatching albendazole-placebo, while Beach 1999 and Fox 2005
provided 250 mg vitamin C tablets.
All trials used a 6 mg/kg dose of DEC except for De Britto 2015,
where 300 mg DEC was given. De Britto 2015 also provided
a placebo for 12 days following treatment with DEC and with
albendazole plus DEC.
Of the four trials that included ivermectin, three trials used doses
varying from 200 to 400 µg/kg (Beach 1999) and 150 to 200 µg/
kg (Dunyo 2000; Simonsen 2004). Dahoma 2000 did not report
the ivermectin dose, but the thesis discussion indicated the dosage
was similar to 200 µg/kg.
Innine trials the drugswere given as a single-dose treatment (Beach
1999; Dahoma 2000; Dunyo 2000; Pani 2002; Simonsen 2004;
Fox 2005; Dreyer 2006; Bockarie 2007; Rizzo 2007); Kshirsagar
2004 and Wamae 2011 provided three annual single doses. Two
trials used more intensive treatment regimens; Gayen 2013 pro-
vided albendazole daily for seven days, and De Britto 2015 pro-
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vided albendazole plus DEC or DEC daily for 12 days.
Study design
Twelve trials were individually-RCTs, andWamae 2011 was a clus-
ter-RCT. The cluster-RCT used households as the unit of ran-
domization, and included 64 households containing 205 adults
and children.
The length of follow-up varied between trials. Dahoma 2000 fol-
lowed up participants for two weeks; Beach 1999 for four months;
Fox 2005 for six months; Dunyo 2000, Simonsen 2004, Dreyer
2006, Rizzo 2007, Gayen 2013, and De Britto 2015 for 12
months; Bockarie 2007 andWamae 2011 for 24months; and Pani
2002 and Kshirsagar 2004 for 36 months.
Outcomes
Measures of transmission potential
All trials reported onmf prevalence anddensity, but themethods of
measurement varied. Beach 1999 and Fox 2005 assessed 20 µL of
bloodwith thick smearmicroscopy.Dunyo 2000, Simonsen 2004,
andWamae 2011 assessed 100µLof bloodusing a counting cham-
ber, and Dahoma 2000 assessed 200µL of blood using a counting
chamber. Seven trials assessed 1 mL blood using membrane filtra-
tion (Pani 2002; Kshirsagar 2004; Dreyer 2006; Bockarie 2007;
Rizzo 2007; Gayen 2013; De Britto 2015). Kshirsagar 2004 also
assessed prevalence in 60µLof bloodwith thick smearmicroscopy.
Markers of adult worm infection
Eight trials reported antigenaemia prevalence (Dunyo 2000; Pani
2002;Kshirsagar 2004; Simonsen 2004; Fox 2005; Bockarie 2007;
Wamae 2011;DeBritto 2015), ofwhich all exceptKshirsagar2004
also reported on antigen density. Five trials assessed antigenaemia
using the TropBio Og4C3 ELISA (Dunyo 2000; Simonsen 2004;
Fox 2005; Bockarie 2007; Wamae 2011); Kshirsagar 2004 used
the BinaxNOWFilariasis ICT; and Pani 2002 and De Britto 2015
used both the ELISA and the immunochromatographic card test
(ICT). Three trials also assessed the effect of treatment on adult
worm FDS by ultrasound scan in male participants (Pani 2002;
Kshirsagar 2004; Dreyer 2006).
Clinical disease
Dunyo 2000 reported on the effect of treatment on clinical disease
(lymphoedema or hydrocoele), including the reduction in grade
or disappearance of clinical disease, the increase in clinical disease
grade, and the appearance of new clinical disease at 12 months
follow-up.
Adverse events
Twelve trials reported on adverse events, but the reporting varied
between trials. Some trials reported the proportion of participants
experiencing adverse events (Dunyo 2000; Pani 2002; Kshirsagar
2004; Rizzo 2007; Wamae 2011; Gayen 2013; De Britto 2015),
while some also reported the incidence of specific systemic adverse
events (Beach 1999; Dahoma 2000; Dunyo 2000; Pani 2002;
Simonsen 2004; Fox 2005; Rizzo 2007), tolerability (Kshirsagar
2004), or calculated scores based on severity and intensity (Beach
1999; Pani 2002; Fox 2005). Dreyer 2006 reported appearance of
intrascrotal nodules in adult worm nests of male participants as a
‘sensitive reaction’ to treatment. Bockarie 2007 did not mention
adverse events post-treatment.
Reported statistical analysis
Individually-randomized trials
The statistical analyses used in the trials for density data are re-
ported in Table 2, and detailed further here. The methods used
to calculate mf density and antigen density and the percentage re-
ductions from baseline to follow-up were inconsistently reported
across trials, and SDs or CIs for density data were absent in all
but one study reporting the geometric mean (Dunyo 2000), and
two studies reporting the arithmetic mean (Pani 2002; Kshirsagar
2004).We obtained CIs from the investigators of Rizzo 2007, and
CIs for density data reported in Fox 2005 were obtained by the au-
thors of the last published version of this review (Addiss 2005). As
so few trials reported any measure of variance or CIs, and the sum-
mary measures presented differed between and within trials (such
as arithmetic means, geometric means, and log means), we could
not pool results for changes in parasite density. Results quoted in
this review are the original trial author’s calculations.
Six trials enrolled individuals irrespective of their infection status
at baseline (Beach 1999; Dunyo 2000; Kshirsagar 2004; Simonsen
2004; Fox 2005; Bockarie 2007), and none reported the overall
change in mf density or antigen density in the total population
enrolled up to 12 months; only Bockarie 2007 provided a mea-
sure of the impact on community mf density at 24 months post-
treatment. Most trials reported geometric meanmf density (Beach
1999;Dunyo 2000; Pani 2002; Simonsen 2004; Fox 2005;Dreyer
2006; Bockarie 2007; Rizzo 2007), and geometric mean antigen
density (Dunyo 2000; Simonsen 2004; Fox 2005);De Britto 2015
reported the log mean mf density and log mean antigen density;
the arithmetic mean was also used for mf density (Pani 2002;
Kshirsagar 2004; Gayen 2013), and for antigen density in Pani
2002. Dahoma 2000 reported mf density data by intensity cate-
gories (“1-20mff, 21-39 mff, 40-59 mff, >60mff”), and Wamae
2011 reported that they calculated geometric mean mf intensity,
but reported log mean mf densities that had not been adjusted for
clustering. We did not include parasite density data fromDahoma
2000 and Wamae 2011 in our analyses.
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Four studies were not explicit about themethod used to accommo-
date zero counts (Beach 1999; Pani 2002; Dreyer 2006; De Britto
2015), but Pani 2002 andDreyer 2006 provided further details on
request; the authors calculated aWilliam’smean (amodification of
the geometric mean to accommodate zero values) (Willams 1937;
Basáñez 1994). Five trials reported using the “n+1” formula be-
fore log transforming the data. Seven trials were not explicit about
the method used to calculate the percentage reduction for density
data (Dunyo 2000; Pani 2002; Kshirsagar 2004; Simonsen 2004;
Dreyer 2006; Bockarie 2007; Gayen 2013), but five of these trials
used the standard percentage change calculation (Dunyo 2000;
Kshirsagar 2004; Simonsen 2004; Bockarie 2007; Gayen 2013).
Dreyer 2006 provided further details on request; this trial used the
method described by Addiss 1993. Beach 1999 and Fox 2005 cal-
culated the geometric mean mf density and antigen density reduc-
tion by dividing the difference between densities before and after
treatment by the pretreatment mf density and log transforming
the results. If pretreatment mf density was less than the density
after treatment, the reduction was deemed to be zero. The trialists
performed this adjustment to eliminate the problem of log trans-
forming a negative value, but this method may bias estimates of
treatment effectiveness, as increases in mf density after treatment
are set to zero.
Two trials reported inappropriate statistical methods for assessing
differences in mf density or antigen density between treatment
groups. Gayen 2013 reported use of a paired t-test, which is an
unsuitable test for comparing different groups. Simonsen 2004
estimated the combined effect on both mf density and antigen
density over the one-year follow-up period using repeated mea-
sures ANOVA, and used pairwise contrast tests to examine differ-
ences between groups at specific time points; however, repeated
measures ANOVA is unsuitable for comparing groups, and results
of pairwise contrast tests were not reported.
Cluster-randomized trials
One cluster-RCT reported the use of a multilevel mixed-effects re-
gression model that adjusted for the cluster design (Wamae 2011);
however, the primary and secondary outcomes of the review were
not adjusted using this model and the authors reported on sub-
groups of microfilaraemic or antigenaemic individuals at follow-
up. It was not possible to adjust the results for clustering by esti-
mating the design effect, as the average cluster size and ICC were
not reported. We also could not estimate the ICC, as no other
cluster-RCTs were included. No outcomes from this trial were
therefore suitable for meta-analysis or comparative analysis, and
we present the authors’ unadjusted results in Appendix 2.
Dealing with missing data
We attempted to clarify aspects of the parasite density data and to
obtain the original data from the authors, but we could not acquire
most of the data that we required from the primary studies for our
analysis. We contacted authors of Beach 1999, Fox 2005, Dreyer
2006, Bockarie 2007, Rizzo 2007, and De Britto 2015, and also
attempted to contact Simonsen 2004, but the email addresses that
we obtained from recently published articles were inactive. At our
request, the authors of Rizzo 2007 provided us with CIs and SDs
of log-transformed density data and the number of participants
reporting adverse events, and the authors of Dreyer 2006 gave us
the raw data files. We contacted the authors of Beach 1999 and
Fox 2005 to obtain the raw study data in order to recalculate the
percentage reduction in density from baseline to follow-up. We
received no response from the authors of Fox 2005. The authors of
Beach 1999were unable to provide this at the time of preparing the
review, due to issues with the file formats. We hope to incorporate
new data analyses from Beach 1999 into any future updates of this
Cochrane Review.
Excluded studies
We excluded 15 trials (reported in 20 records) at the full-text
screening stage, because they did not include the comparison
groups or participant population sought for the review, the meth-
ods and results were not coherent or clearly expressed, the number
of participants randomized for each group was very small with
differential losses to follow-up between treatment groups, or they
were not an RCT. See Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2 and Figure 3 for ‘Risk of bias’ summaries, and
Characteristics of included studies section for details of the risks
of bias and methods used in each trial.
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Figure 2. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ‘Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All trials described themselves as randomized. We judged the risk
of bias to be low in six trials that described a method of randomiza-
tion (Beach 1999; Dahoma 2000; Dunyo 2000; Simonsen 2004;
Fox 2005; Rizzo 2007), and unclear in seven trials that did not
provide further details (Pani 2002; Kshirsagar 2004; Dreyer 2006;
Bockarie 2007; Wamae 2011; Gayen 2013; De Britto 2015).
We judged eight trials to be at low risk of bias for allocation con-
cealment (Beach 1999; Dahoma 2000; Dunyo 2000; Pani 2002;
Kshirsagar 2004; Simonsen 2004; Fox 2005; Gayen 2013). We
judged Rizzo 2007 to be at high risk of bias, as allocation of par-
ticipants was not concealed. We judged four trials to be at unclear
risk, due to insufficient information (Dreyer 2006; Bockarie 2007;
Wamae 2011; De Britto 2015).
Blinding
Nine trials described themselves as “double blind”. For blind-
ing of participants and personnel, five studies described blinding
and we judged these to be at low risk of bias (Beach 1999; Pani
2002; Kshirsagar 2004; Fox 2005; Gayen 2013).We judged Rizzo
2007 to be at high risk of bias, as they did not use blinding. We
judged details of blinding to be unclear in seven trials (Dahoma
2000;Dunyo 2000; Simonsen 2004;Dreyer 2006; Bockarie 2007;
Wamae 2011; De Britto 2015).
For blinding of outcome assessors, seven trials described blinding
of outcome assessment and we judged these to be at low risk of bias
(Beach 1999; Dahoma 2000; Dunyo 2000; Pani 2002; Kshirsagar
2004; Fox 2005; Rizzo 2007). Six trials did not provide details
of outcome assessor blinding and we judged risk of bias to be
unclear (Simonsen 2004; Dreyer 2006; Bockarie 2007; Wamae
2011; Gayen 2013; De Britto 2015).
Incomplete outcome data
About half the included studies (6/13) reported that more than
85% of all randomized individuals had been followed up, and we
judged these studies to be at low risk of bias (Dahoma 2000; Pani
2002; Dreyer 2006; Rizzo 2007; Gayen 2013; De Britto 2015).
We judged six studies to be at high risk of bias due to attrition,
as losses or exclusions of participants during the follow-up period
were considerable (Beach 1999; Kshirsagar 2004; Simonsen 2004;
Fox 2005; Bockarie 2007;Wamae 2011).We judged Dunyo 2000
to be at unclear risk.
We judged Beach 1999, Simonsen 2004, Fox 2005, and Bockarie
2007 to be at high risk of bias, as they excluded randomized par-
ticipants who did not have pre- and post-treatment blood sam-
ples. We judged Kshirsagar 2004 to be at high risk of bias as the
authors included a very small subset of randomized participants
in a separate efficacy analysis. Wamae 2011 (cluster-RCT) did not
clearly report the number of individuals that were analysed among
those randomized. Dunyo 2000 analysed 1181 of 1425 partici-
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pants (17.1% lost) at 12 months, with losses attributed to par-
ticipant absence during survey times and some being unwilling
to have repeated finger pricks. Sixty-seven of the 340 mf-positive
participants (20%) were also lost to follow-up.
Selective reporting
Eight trials had no obvious evidence of selective reporting and
we judged these to be at low risk of bias (Dahoma 2000; Dunyo
2000; Pani 2002; Simonsen 2004; Dreyer 2006; Rizzo 2007;
Gayen 2013; De Britto 2015). Four trials had evidence of selective
reporting and we judged them to be at high risk of bias (Kshirsagar
2004; Fox 2005; Bockarie 2007; Wamae 2011). We judged Beach
1999 to be at unclear risk, as not all the adverse events prespecified
in the Methods were reported.
Other potential sources of bias
We judged three studies to be at high risk of bias due to other poten-
tial sources of bias (Simonsen 2004; Wamae 2011; Gayen 2013).
Gayen 2013 reported an inappropriate statistical analysis (paired
t-test) for testing for differences between treatments, which could
bias interpretation of the intervention effects. Simonsen 2004 did
not report the findings of statistical tests for differences between
groups at specific time points, but reported a significant effect for
the intervention over time using repeated measures ANOVA. We
rated one cluster-RCT at high risk of bias due to incorrect analysis
(some data were not adjusted for clustering) and the number of
clusters and participants followed up or included in the analyses
was not clearly reported (Wamae 2011).
We judged two studies to have unclear risk of bias (Beach 1999;
Fox 2005). For parasite density data outcomes, the authors of
Beach 1999 and Fox 2005 omitted increases in density prior to
estimating the percentage reduction between baseline and follow-
up. This simply provides an assessment of the decrease in density
only in people experiencing a decrease.Whilst this rule was applied
to both intervention and control groups, we were uncertain of the
effect of this on the estimate, or exactly what the estimate was
measuring.
Effects of interventions
See: Summaryof findings for themain comparisonAlbendazole
alone or added to a microfilaricidal drug for lymphatic filariasis;
Summary of findings 2Albendazole alone for lymphatic filariasis;
Summary of findings 3Albendazole added toDEC for lymphatic
filariasis;Summaryof findings 4Albendazole added to ivermectin
for lymphatic filariasis
The first set of analyses examine albendazole given alone or added
to amicrofilaricidal drug; and the subsequent analyses are grouped
by the different background drugs (placebo, DEC, ivermectin).
For each comparison, we present the results at the longest follow-
up (up to 12 months) from each study, and include all individuals
enrolled as the denominator where possible.
Within each different background drug analysis, we also analysed
different follow-up time points and stratified by the following.
• People known to be infected
• People both infected and uninfected in community studies
The data on mf density and antigen density are presented in ‘Ad-
ditional tables’; this was expressed differently across studies, often
with no measure of variance, and we therefore summarized it nar-
ratively in the text.
Overall effect
Albendazole alone or added to a microfilaricidal drug
One cluster-randomized trial randomized households, and then
only reported on people found to be infected and who gave blood
at baseline (Wamae 2011). The authors reported the mean log
density in a graph but this was complicated by interaction, and a
logistic regression analysis was not clear as to who was included,
and so further interpretation was not possible (see Description of
studies above). The results are in Appendix 2.
Mf prevalence
Treatment with albendazole had no effect on mf prevalence at the
longest follow-up up to 12 months (5027 participants, 12 trials;
Analysis 1.1).
Mf density
Eleven trials reported the effects of albendazole on mf density.
Pani 2002, Rizzo 2007, Gayen 2013, and De Britto 2015 only
enrolledmf-positive people at baseline; Dreyer 2006 only enrolled
people with adult worms detected by ultrasound, irrespective of
mf status; Beach 1999, Dunyo 2000, Kshirsagar 2004, Simonsen
2004, Fox 2005, and Bockarie 2007 recruited mf-positive and -
negative participants, but only reported density in people who
were mf-positive at baseline; none reported the overall change in
mf density in the total population enrolled.
Overall, albendazole was associated with inconsistent reductions
in mf density up to six months (1216 participants, 10 trials; Table
3) and at 12 months (1052 participants, 9 trials; Table 4).
Up to six months, there were four studies that gave albendazole
alone, and we assessed three of these as being at high risk of bias
(Gayen 2013 used the arithmetic mean, Beach 1999 and Fox 2005
excluded increases in mf density post-treatment). One study (119
participants), assessed as low or unclear risk of bias, suggested
an effect on density although this was not evaluated statistically
(Dunyo 2000); and the other studies are difficult to interpret, given
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the risks of bias. When albendazole was used with other drugs, the
results were similarly inconsistent or problematic to interpret.
At 12 months, a similar pattern emerged with albendazole alone,
where we rated one study at high risk of bias (Gayen 2013 used
the arithmetic mean), and an effect on density was suggested in
Dunyo 2000, although this was not statistically significant (P =
0.10). When used with other drugs, the results showed little or no
effect of albendazole.
Antigenaemia prevalence
Treatment with albendazole had no effect on antigen prevalence
at the longest follow-up (3774 participants, 7 trials; Analysis 1.2).
Antigen density
Five trials reported the effects of albendazole on antigen density.
Pani 2002 and De Britto 2015 only enrolled people mf-positive at
baseline; Dunyo 2000, Simonsen 2004, and Fox 2005 recruited
infected and uninfected participants, but only reported density in
people who were antigen-positive at baseline; none reported the
overall change in antigen density in the total population enrolled.
Overall, albendazole was not associated with greater reductions in
antigen density between six and 12 months post-treatment (1374
participants, 5 trials; Table 5).
Two studies gave albendazole alone; Fox 2005 was assessed at high
risk of bias (the authors excluded increases in antigen density post-
treatment) and Dunyo 2000 at low or unclear risk of bias. Dunyo
2000 included 208 participants and suggested a large difference
in the antigen density percentage reductions between albendazole
andplacebo; however, albendazole alone reduceddensity by 16.9%
while the placebo group increased by 47.5%, and the difference
was not statistically significant (P = 0.11). The results showed little
or no effect of albendazole when used with other drugs.
Adult worm prevalence detected by ultrasound
There was no difference associated with adding albendazole to
DEC for reducing adult worm prevalence in men examined for
FDS by ultrasonography at the longest follow-up up to 12 months
(165 participants, 3 trials; Analysis 1.3). However, the individual
trials were all small and underpowered.
Clinical disease: new and pre-existing
Treatment with albendazole had no effect on new (535 partici-
pants, 1 trial; Analysis 1.4) or existing clinical disease (85 partici-
pants, 1 trial; Analysis 1.5); however, the trial was underpowered
for clinical outcomes.
Adverse events
Treatment with albendazole had no effect on the number of par-
ticipants experiencing adverse events (2894 participants, 6 trials;
Analysis 1.6).
Sensitivity analysis
In the sensitivity analyses including only trials where the risk of
bias for allocation concealment was low, no difference between
intervention and control groups in mf prevalence, antigenaemia
prevalence, adult worm prevalence detected by ultrasound, or ad-
verse events was evident. We do not present the sensitivity anal-
yses here, as the results did not differ from those in the primary
analyses.
Effects stratified by background drug
In the absence of any substantive evidence for an overall effect
of albendazole, this became our main finding. However, we pro-
vide comparisons of albendazole grouped by background drug, as
countries and policy-makers may want to scrutinize the effective-
ness of individual treatment regimens.
Albendazole versus placebo
No trials assessed adult worm prevalence (FDS) using ultrasound.
Mf prevalence
Treatment with albendazole had no effect on mf prevalence at the
longest follow-up (1406 participants, 4 trials; Analysis 2.1).
Treatment with albendazole had no effect on mf prevalence up to
six months (Analysis 2.2), or at 12 months (Analysis 2.3), irre-
spective of baseline infection status.
Mf density
Four trials reported the effects of albendazole onmf density. Gayen
2013 only enrolled people mf-positive at baseline; Beach 1999,
Dunyo 2000, and Fox 2005 recruited mf-positive and -negative
participants, but only reported density in people mf-positive at
baseline; none reported the overall change in mf density in the
total population enrolled.
Albendazole was associated with greater reductions in mf density
up to sixmonths (285participants, 4 trials; Table 3) and12months
(169 participants, 2 trials; Table 4).
Up to six months, there were four studies that assessed albendazole
against placebo, but the magnitude of the effect of albendazole
varied. One study (119 participants) suggested an effect on density
(Dunyo 2000), but this was not statistically evaluated. Three stud-
ies were at high risk of bias: Beach 1999 and Fox 2005 excluded
increases in mf density post-treatment, and Gayen 2013 used the
arithmetic mean; and could not be meaningfully interpreted.
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At 12months, therewere two studies that gave albendazole;Dunyo
2000 included 143 participants and reported an effect of albenda-
zole on density but this was not statistically significant (P = 0.10);
the results of Gayen 2013 were difficult to interpret, as this study
included 33 participants and was at high risk of bias.
Antigenaemia prevalence
Treatment with albendazole had no effect on antigen prevalence
at the longest follow-up (1054 participants, 2 trials; Analysis 2.4).
Treatment with albendazole had no effect on antigen prevalence in
people who were infected and uninfected at six months (Analysis
2.5) and 12 months (Analysis 2.6) post-treatment; and no effect
at 12 months follow-up in participants who were antigenaemic at
baseline (Analysis 2.6).
Antigen density
Two trials reported the effects of albendazole on antigen density
(Dunyo 2000; Fox 2005). Both trials recruited antigen-positive
and -negative participants, but only reported density in people
antigen-positive at baseline; none reported the overall change in
antigen density in the total population enrolled.
Albendazole was not associated with significantly greater reduc-
tions in antigen density between six and 12 months post-treat-
ment (371 participants, 2 trials; Table 5).
Dunyo 2000 included 208 participants and density was reduced
by 16.9% with albendazole, while density increased by 47.5%
with placebo, but the difference was not statistically significant (P
= 0.11). Fox 2005 reported no difference with albendazole in a
study including 163 participants (P > 0.05), but we judged it to be
at high risk of bias (the authors excluded increases in mf density
post-treatment).
Clinical disease: new and pre-existing
Treatment with albendazole had no effect on new (255 partici-
pants, 1 trial; Analysis 2.7: subgroup 1) or existing clinical disease
(Analysis 2.7: subgroups 2 and 3); however, Dunyo 2000 was un-
derpowered for clinical outcomes.
Adverse events
Treatment with albendazole had no effect on the number of par-
ticipants experiencing adverse events (678 participants, 2 trials;
Analysis 2.8).
Beach 1999 and Fox 2005 did not provide data in a form that
we could use in the meta-analysis. Beach 1999 reported adverse
reactions as generally mild and well tolerated, with no significant
difference between participants receiving placebo or albendazole.
Fox 2005 reported statistically significant reductions (P < 0.05) in
myalgias and cough for albendazole compared with placebo, but
no statistically significant differences in headache, fever, or mean
treatment impact score.
Beach 1999,Dunyo 2000, andFox 2005 reported that no localized
inflammatory reactions were detected following treatment, and
Gayen 2013 did not report this. No serious adverse events were
reported in any trials.
Sensitivity analysis
In the sensitivity analyses including only trials where the risk of
bias for allocation concealment was low, no difference between
albendazole and placebo groups in mf prevalence, antigenaemia
prevalence, or adverse events was evident. We do not present the
sensitivity analyses here, as the results did not differ from those in
the primary analyses.
Albendazole plus DEC versus DEC
No trials assessed new or pre-existing clinical manifestations post-
treatment.
One cluster-randomized trial randomized households, and then
only reported on people found to be infected and who gave blood
at baseline (Wamae 2011). The trial authors reported themean log
density in a graph but a logistic regression analysis was not clear
as to who was included, and was complicated by interaction, so
further interpretation was not possible (see Description of studies
above). The results are in Appendix 2.
Mf prevalence
Adding albendazole to DEC had no effect on mf prevalence at the
longest follow-up (1102 participants, 7 trials; Analysis 3.1).
There was no benefit of adding albendazole to DEC up to six
months (Analysis 3.2) or at 12 months post-treatment (Analysis
3.3), irrespective of baseline infection status. There was moderate
to substantial heterogeneity detected up to six months (Analysis
3.2; I2 = 79%) and at 12 months (Analysis 3.3; I2 = 61%) in
the microfilaraemic participant subgroups, but subgroup analysis
for dose seemed to explain this. There were not enough trials to
formally investigate the source of heterogeneity.
There was no difference in mf prevalence at 24 months follow-up
in participants who were all mf- or all antigen-positive at baseline
(Analysis 3.4). There was no benefit of adding albendazole toDEC
for individuals infected and uninfected at baseline after a single
dose or two annual doses; or at 36 months after three annual doses
(Analysis 3.5).
Mf density
Seven trials reported the effects of adding albendazole to DEC on
mf density. Pani 2002, Rizzo 2007, and De Britto 2015 only en-
rolled microfilaraemic individuals; Dreyer 2006 only enrolled in-
dividuals with FDS irrespective of mf status; and Kshirsagar 2004,
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Fox 2005, and Bockarie 2007 recruited mf-positive and -negative
participants, but only reported density in subsets of individuals
enrolled at baseline; none reported the overall change in mf den-
sity in the total population enrolled up to 12 months follow-up.
Overall, albendazole was associated with inconsistent effects on
mf density up to six months (559 participants, 6 trials; Table 3),
and was not associated with greater reductions in mf density at 12
months (535 participants, 6 trials; Table 4).
Up to six months, there were six studies that compared albenda-
zole added to DEC to DEC alone. Five studies showed little or no
effect with albendazole, and one study reported a slightly greater
reduction with DEC alone (Dreyer 2006); there was no significant
difference (P > 0.05) in the four trials that statistically evaluated
this. One study assessed at high risk of bias (Fox 2005 excluded
increases in mf density post-treatment) reported a significant re-
duction (P = 0.02) with the addition of albendazole, but this is
difficult to interpret given the risk of bias.
At 12 months, there were five studies at low or unclear risk of bias
that showed no effect of adding albendazole, and Dreyer 2006
reported a slightly greater reduction with DEC alone; there was
no statistically significant difference (P > 0.05) in four studies that
tested this.
At 24 months, there was no effect of adding albendazole to DEC
in two studies after one dose (Pani 2002; Bockarie 2007), and one
study after two annual doses (Kshirsagar 2004); reported as not
significant in two studies (P > 0.05) (795 participants, 3 trials;
Table 6). At 36 months, two very small trials at high risk of bias
reported no effect with albendazole after one annual dose (Pani
2002), or three annual doses (Kshirsagar 2004) (57 participants,
2 trials; Table 6).
Antigenaemia prevalence
There was no effect of adding albendazole to DEC in reducing
antigen prevalence at the longest follow-up (954 participants, 5
trials; Analysis 3.6).
Therewas nobenefit of albendazole plusDECat sixmonths (Anal-
ysis 3.7) or at 12 months (Analysis 3.8) post-treatment, irrespec-
tive of baseline infection status. Treatment with albendazole plus
DEC had no additive effect at 24 months follow-up (Analysis 3.9)
after either one annual dose or two annual doses; and no effect at
36 months (Analysis 3.10) after either one annual dose or three
annual doses.
Antigen density
Three trials reported the effects of adding albendazole to DEC on
antigen density. Pani 2002 and De Britto 2015 only recruited mf-
positive participants; Fox 2005 recruited antigen-positive and -
negative participants and reported density in people antigenaemic
at baseline, not the overall change in antigen density in the total
population enrolled.
Adding albendazole to DEC was not associated with greater re-
ductions in antigen density between six and 12 months (270 par-
ticipants, 3 trials; Table 5).
One study was at low or unclear risk of bias (De Britto 2015), and
two studieswere at high risk of bias (Fox 2005 excluded increases in
mf density post-treatment; Pani 2002 used the arithmetic mean).
All three studies reported little or no effect of adding albendazole
to DEC, reported as not significant (P > 0.05) in two studies that
statistically evaluated this.
At 24 and 36 months after a single treatment, one small study
at high risk of bias reported density was near pre-treatment levels
in both groups after 24 months (Pani 2002), and at 36 months
density had increased in the albendazole plus DEC group but
remained at pre-treatment levels with DEC alone (35 participants,
1 trial; Table 7). At 24 months after a single treatment, Bockarie
2007 reported antigen concentration decreased from high to low
in 16 (18.8%) participants with albendazole plus DEC, and 9
(14.7%) participants with DEC alone.
Adult worm prevalence detected by ultrasound
There was no difference with albendazole plus DEC for reducing
adult worm prevalence in men examined for FDS by ultrasound
at the longest follow-up (165 participants, 3 trials; Analysis 3.11).
However, the individual trials were all small and underpowered.
There was no benefit of adding albendazole to DEC at six months
(Analysis 3.12) or at 12 months (Analysis 3.13) post-treatment,
or at 24 months (Analysis 3.14) after single dose or two annual
doses, irrespective of baseline infection status.
Adverse events
Treatment with albendazole plus DEC had no effect on the num-
ber of participants experiencing adverse events (1589 participants,
4 trials; Analysis 3.15). Adverse events were systemic in three trials
and De Britto 2015 did not provide details.
There was no difference in adverse events that interferedwith daily
activity when albendazole was added to DEC (Analysis 3.16: sub-
group 2). One small trial reported localized inflammatory reac-
tions following treatment, but no difference between treatment
groups (Analysis 3.16: subgroup 3). One small trial that enrolled
only men with FDS reported intrascrotal nodules (a “sensitive re-
action” to antifilarial drugs) at seven days post-treatment; nodules
were detected at the site of 21 (46.7%) adult worm nests with
DEC alone compared to 2 (6.1%) with albendazole plus DEC (P
= 0.002) (Dreyer 2006).
Bockarie 2007 did not report adverse events, and Fox 2005 did
not did not provide data in a form that we could use in meta-
analysis. Fox 2005 reported that adverse reactions were generally
mild and well tolerated, with no statistically significant differences
in specific symptoms or treatment impact scores between groups.
Kshirsagar 2004 also assessed a smaller subset of individuals from
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the large safety study who were retreated at 12 months and 24
months, but differences between groups were not reported.
No life-threatening adverse events or adverse events requiring hos-
pitalization were reported in any trials.
Sensitivity analysis
In the sensitivity analyses including only trials where the risk of
bias for allocation concealment was low, no difference between
albendazole plus DEC and DEC groups in mf prevalence, antige-
naemia prevalence, adult worm prevalence by ultrasound, or ad-
verse events was evident. We do not present the sensitivity anal-
yses here, as the results did not differ from those in the primary
analyses.
Albendazole plus ivermectin versus ivermectin
No trials assessed adult worm prevalence (FDS) by ultrasound.
Mf prevalence
Treatment with albendazole plus ivermectin had no effect on mf
prevalence at the longest follow-up (2519 participants, 4 trials;
Analysis 4.1). There was moderate heterogeneity detected (I2 =
65%) in this analysis, but subgroup analysis for length of follow-
up seemed to explain this. There were not enough trials to formally
investigate the source of heterogeneity.
Treatment with albendazole plus ivermectin did not have a statis-
tically significant effect on mf prevalence up to six months (Anal-
ysis 4.2) or at 12 months (Analysis 4.3), irrespective of baseline
infection status. Moderate to substantial heterogeneity was also
detected within the subgroups of microfilaraemic participants (I
2 = 75%) and infected and uninfected participants (I2 = 63%) at
six months (Analysis 4.2). This also appeared to be explained by
length of follow-up, but could not be formally investigated.
Mf density
Four trials reported the effects of adding albendazole to ivermectin
on mf density. Beach 1999, Dunyo 2000, and Simonsen 2004
recruited mf-positive and mf-negative participants, but only re-
ported density in people mf-positive at baseline; none reported
the overall change in the population mf density post-treatment.
Dahoma 2000 assessed mf density by density categories and we
did not include these data in our analysis.
Adding albendazole to ivermectin was associated with inconsistent
reductions in mf density up to six months (372 participants, 3
trials; Table 3), and was not associated with greater reductions at
12 months (348 participants, 2 trials; Table 4).
Up to six months, there were three studies that gave albendazole
with ivermectin, and one of these was assessed at high risk of bias
(Beach 1999 excluded increases in mf density post-treatment).
Two studies, Dunyo 2000 and Simonsen 2004, which we assessed
as at low or unclear risk of bias, reported little or no effect on
density with albendazole. Beach 1999 reported a significant effect
(P < 0.001) but what this means is unclear, given the risk of bias.
At 12 months, there were two trials at low or unclear risk of bias
(Dunyo 2000; Simonsen 2004). There was little or no difference
in density with albendazole, reported as not significant (P = 0.80)
in one study that statistically tested this.
Antigenaemia prevalence
Therewas nodifference in antigenprevalence at the longest follow-
up up to 12 months (1766 participants, 2 trials; Analysis 4.4).
There was no benefit of adding albendazole to ivermectin at six
months (Analysis 4.5) or 12months post-treatment (Analysis 4.6),
irrespective of baseline infection status.
Antigen density
Two trials reported the effects of adding albendazole to ivermectin
on antigen density (Dunyo 2000; Simonsen 2004). Both trials
recruited antigen-positive and -negative participants, but only re-
ported density in people antigen-positive at baseline; none re-
ported the overall change in the population antigen density post-
treatment.
Albendazole was associated with marginal reductions in antigen
density at 12 months (733 participants, 2 trials; Table 5).
A slightly greater reduction in density with albendazole was re-
ported in Dunyo 2000 (10.9% difference) and Simonsen 2004
(17.1%difference); the antigen density post-treatmentwith alben-
dazole was not significantly different (P > 0.80) in Dunyo 2000.
Clinical disease
At 12 months post-treatment, adding albendazole to ivermectin
had no effect on new (280 participants, 1 trial; Analysis 4.7: sub-
group 1) or existing clinical disease (Analysis 4.7: subgroups 2
and 3); however, Dunyo 2000 was underpowered for clinical out-
comes.
Adverse events
Treatment with albendazole plus ivermectin had no effect on the
number of participants experiencing adverse events (627 partici-
pants, 1 trial; Analysis 4.8).
Beach 1999, Dahoma 2000, and Simonsen 2004 did not provide
data in a form that we could use in meta-analysis. Simonsen 2004
did not report the number of participants with adverse events in
each group, but reported that all reactions were mild, and no sig-
nificant relationship between headache or fever and the treatment
given (P = 0.42 and P = 0.96). Beach 1999 reported that adverse
reactions were generally mild, with no significant differences (P >
0.05) in the frequency or severity of symptoms between groups.
Dahoma 2000 reported significant differences in fever (P = 0.045)
23Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
and dizziness (P = 0.029) with ivermectin alone, and significant
differences (P = 0.012) in headaches were reported with the com-
bination treatment.
No serious or severe adverse reactions were reported in any of the
trials. No localized inflammatory reactions were observed in Beach
1999 and Dunyo 2000, and Dahoma 2000 and Simonsen 2004
did not report this.
Sensitivity analysis
In the sensitivity analyses including only trials where the risk of
bias for allocation concealment was low, no difference between
albendazole plus ivermectin and ivermectin groups in mf preva-
lence, antigenaemia prevalence, or adverse events was evident. We
do not present the sensitivity analyses here, as the results did not
differ from those in the primary analyses.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Albendazole alone for lymphatic filariasis
Patient or population: people with lymphatic f ilariasis or communit ies where lymphatic f ilariasis is endemic
Setting: Ghana, Hait i and India
Intervention: albendazole
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with albendazole
Microf ilaraemia (mf )
prevalence
follow-up: range 4
months to 12 months
207 per 1000 203 per 1000
(168 to 246)
RR 0.98
(0.81 to 1.19)
1406
(4 RCTs)
⊕⊕⊕⊕
HIGHa,b
Albendazole makes lit -
t le or no dif ference to
mf prevalence.
Mf density
follow-up: range 4
months to 6 months
Trend favoured albendazole to a variable extent.
Albendazole reduced the geometric mean mf
density by 28.7% to 61.1%. Placebo reduced the
geometric mean mf density up to 17.2%, but the
density also increased by 20.6%.c
- 285
(4 RCTs)
⊕©©©
VERY LOWd,e,f
Due to risk of bias, incon-
sistency, and imprecision
We do not know if al-
bendazole has an ef fect
on mf density.
Mf density
follow-up: 12 months
No trend. In one study that reported the geometric
mean, albendazole reduced mf density by 68.
5% and in the placebo group the reduct ion was
13%; however, the authors reported no signif icant
dif f erence with albendazole (P > 0.05).g
- 169
(2 RCTs)
⊕©©©
VERY LOWh,i
Due to inconsistency and
imprecision
We do not know if al-
bendazole has an ef fect
on mf density.
Ant igenaemia preva-
lence
follow-up: range 6
months to 12 months
355 per 1000 380 per 1000
(323 to 444)
RR 1.07
(0.91 to 1.25)
1054
(2 RCTs)
⊕⊕⊕⊕
HIGH
Albendazole makes lit -
t le or no dif ference
to ant igenaemia preva-
lence
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Antigen density
follow-up: range 6
months to 12 months
Trend showed lit t le or no ef fect of albendazole.
Albendazole reduced the geometric mean anti-
gen density by 3.2% to 16.9%, and the placebo
group ant igen density was reduced by 1.7% and
also increased by 47.5%.j
- 371
(2 RCTs)
⊕©©©
VERY LOWk,l,m
Due to risk of bias and im-
precision
We do not know if al-
bendazole has an ef fect
on ant igen density
Adult worm prevalence
detected by ultrasound
- not measured
- - - - - Adult worm prevalence
detected by ultrasound
was not measured for
this comparison
Adverse events 106 per 1000 101 per 1000
(65 to 157)
RR 0.95
(0.61 to 1.48)
678
(2 RCTs)
⊕⊕⊕©
MODERATEn,o
Due to imprecision
Albendazole probably
makes lit t le or no dif fer-
ence to adverse events
* The risk in the intervent ion group (and its 95% CI) is based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95%CI).
Abbreviat ions: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aNot downgraded for risk of bias: most information is f rom studies at low or unclear risk of bias. Three studies had unclear
or high risk of bias for attrit ion, but numbers of part icipants followed up were comparable between groups in each study.
We judged plausible bias unlikely to seriously alter the results.
bNot downgraded for imprecision: borderline suf f icient events to meet opt imal information size (289 total events), and the
95% CI around the pooled est imate of ef fect includes lit t le or no ef fect and excludes clinically appreciable benef it and harm.
We used a relat ive risk reduct ion (RRR) of 25% as a cut-of f for imprecision.
cOf the three studies that reported the geometric mean; one study reported an ef fect of albendazole (P < 0.05), one study
reported no ef fect (P > 0.05), and one study did not stat ist ically test this. One study report ing the arithmetic mean suggested
a large benef it with albendazole, but we judged this to be an inappropriate measure for skewed data.
dDowngraded by one for risk of bias: we judged the analyt ical methods used by Beach 1999 and Fox 2005 to obtain the
change in density f rom baseline to follow-up to be at high risk of bias.
eDowngraded by one for inconsistency: the benef it of albendazole and the magnitude of ef fect was inconsistent.2
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fDowngraded by two for imprecision: the opt imal information size was not met. There was considerable variat ion in the
ef fects of albendazole on geometric mean mf density; ranging f rom an ef fect in one study (P < 0.05), an apparent ly large
ef fect in one study that was not stat ist ically evaluated, and no ef fect in one study (P > 0.05). One study reported the arithmetic
mean. We judged that the range of values could include a meaningful ef fect and no ef fect.
gOne study reported the arithmetic mean and showed a large benef it with albendazole, but we judged it to be an inappropriate
measure for skewed data.
hDowngraded by one for inconsistency: two studies reported a greater reduct ion in mf density with albendazole, but the
magnitude of ef fect was unclear. One study reported the geometric mean and reported no ef fect of albendazole (P >0.05),
and one study reported the arithmetic mean and did not test for dif f erences.
iDowngraded by two for imprecision: the opt imal information size was not met. One study reported the geometric mean mf
density and an apparent ly large but underpowered ef fect (P > 0.05). One study suggested a large reduct ion in the arithmetic
mean with albendazole and did not stat ist ically evaluate the ef fect. We judged that the range of values could include a
meaningful ef fect and no ef fect.
jBoth studies reported that there was no ef fect using albendazole (P > 0.05).
kDowngraded by one for risk of bias: we judged the analyt ical methods used by Fox 2005 to obtain the change in density f rom
baseline to follow-up to be at high risk of bias.
lNot downgraded for inconsistency: we found lit t le to no ef fect of albendazole consistent ly across the studies. We judged the
direct ion and the magnitude of ef fect to be consistent across studies.
mDowngraded by two for imprecision: the opt imal information size was not met. Two studies reported geometric mean antigen
density and no benef it of using albendazole (P > 0.05). We judged that the range of values would likely include lit t le or no
ef fect and exclude appreciable benef it or harm, but we can not be certain with no ef fect est imate or measure of precision.
nNot downgraded for indirectness: albendazole regimens dif fered, one study provided single dose 400 mg albendazole and
one study provided daily dose 400 mg albendazole for seven days. However, we judge this does not have serious indirectness.
oDowngraded by one for imprecision: insuf f icient events to meet opt imal information size. The 95% CI around the pooled
est imate of ef fect includes both no ef fect and appreciable benef it and harm, using a relat ive risk reduct ion (RRR) of 25%.
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Albendazole added to DEC for lymphatic filariasis
Patient or population: people with lymphatic f ilariasis or communit ies where lymphatic f ilariasis is endemic
Setting: Brazil, Hait i, India and Papua New Guinea
Intervention: albendazole plus DEC
Comparison: DEC
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with DEC Risk with albendazole
plus DEC
Microf ilaraemia (mf )
prevalence
follow-up: range 6
months to 12 months
262 per 1000 236 per 1000
(197 to 286)
RR 0.90
(0.75 to 1.09)
1102
(7 RCTs)
⊕⊕⊕©
MODERATEa,b
Due to imprecision
Albendazole probably
makes lit t le or no dif fer-
ence to mf prevalence
Mf density
follow-up: range 1
months to 6 months
No trend. The dif ference between the albenda-
zole plus DEC and the DEC groups percentage
reduct ions f rom baseline ranged f rom a 30%
greater reduct ion with albendazole plus DEC to a
13.6% greater reduct ion with DEC alone.c
- 559
(6 RCTs)
⊕©©©
VERY LOWd,e,f
Due to risk of bias, incon-
sistency, and imprecision
We do not know if al-
bendazole has an ef fect
on mf density.
Mf density
follow-up: 12 months
Trend showed lit t le or no ef fect of albendazole.
The dif ference between the albendazole plus DEC
and the DEC groups percentage reduct ions f rom
baseline ranged f rom a 5.6% greater reduct ion
with albendazole plus DEC to a 15.8% greater
reduct ion with DEC alone.g
- 535
(6 RCTs)
⊕⊕©©
LOWh,i
Due to imprecision
Albendazole may make
lit t le or no dif ference to
mf density.
Ant igenaemia preva-
lence
follow-up: range 6
months to 12 months
503 per 1000 518 per 1000
(463 to 574)
RR 1.03
(0.92 to 1.14)
954
(5 RCTs)
⊕⊕⊕⊕
HIGHj
Albendazole makes lit -
t le or no dif ference
to ant igenaemia preva-
lence
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Antigen density
follow up: range 6
months to 12 months
Trend showed lit t le or no ef fect of albendazole.
The dif ference between the albendazole plus DEC
and the DEC groups percentage reduct ions f rom
baseline ranged f rom a 9.7%greater reduct ion in
the geometric mean to a 10.7%greater reduct ion
in the log mean with albendazole plus DEC.k
- 270
(3 RCTs)
⊕©©©
VERY LOWh,l,m
Due to risk of bias and im-
precision
We do not know if al-
bendazole has an ef fect
on ant igen density
Adult worm prevalence
detected by ultrasound
follow up: 12 months
268 per 1000 311 per 1000
(193 to 499)
RR 1.16
(0.72 to 1.86)
165
(3 RCTs)
⊕⊕©©
LOWn,o,p
Due to indirectness and
imprecision
Albendazole may make
lit t le or no dif ference to
adult worm prevalence
detected by ultrasound
Adverse events 240 per 1000 225 per 1000
(189 to 266)
RR 0.94
(0.79 to 1.11)
1589
(4 RCTs)
⊕⊕⊕⊕
HIGHq
Albendazole makes lit -
t le or no dif ference to
adverse events.
* The risk in the intervent ion group (and its 95% CI) is based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95%CI).
Abbreviat ions: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aNot downgraded for inconsistency: I2 of 40% was explained through subgroup analysis. The heterogeneity was a result of
one study which used a more intensive treatment regimen (daily dose for 12 days) compared to the other six studies (single
dose). We therefore judged inconsistency does not seem to be a serious issue.
bDowngraded by one for imprecision: insuf f icient events to meet opt imal information size (276 total events). Using a relat ive
risk reduct ion (RRR) of 25% as a cut-of f for imprecision, the 95% CI around the pooled est imate of ef fect includes no ef fect
and no clinically appreciable harm, but the upper boundary of the CI represents a 25%RRR. We therefore judge that the 95%CI
around the pooled est imate of ef fect could include clinically appreciable benef it if the opt imal information size had been met.
cOne study reported an ef fect of adding albendazole to DEC (P < 0.05) and four studies reported no ef fect (P > 0.05). Five
studies reported geometric means and one study reported the log mean.
dDowngraded by one for risk of bias: we judged the analyt ical methods used by Fox 2005 to obtain the change in density f rom
baseline to follow-up to be at high risk of bias.
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eDowngraded by one for inconsistency: the direct ion and magnitude of ef fect reported varied in favour of both albendazole
plus DEC and DEC alone. We judged the ef fects of adding albendazole to DEC to be inconsistent.
fDowngraded by two for imprecision: the opt imal information size was met. The ef fect of adding albendazole to DEC varied
considerably. One trial reported an ef fect of adding albendazole (P < 0.05) and no ef fect was reported in the others (P > 0.05).
We judged that the range of values would likely include a meaningful ef fect and no ef fect.
gFour studies report ing the geometric mean reported no ef fect of adding albendazole to DEC (P > 0.05). One study reported
the log mean and one study reported the arithmetic mean, no ef fect was seen.
hNot downgraded for inconsistency: the direct ion and magnitude of the ef fect was consistent; we found no benef it of adding
albendazole to DEC consistent ly across the studies.
iDowngraded by two for imprecision: the opt imal information size was met. No ef fect of adding albendazole to DEC was
consistent ly reported across the studies; all studies reported no ef fect on geometric mean mf density (P > 0.05). We judged
that the range of values would likely include lit t le or no ef fect and exclude appreciable benef it or harm, but we can not be
certain as there is no est imate of ef fect or measure of precision.
jNot downgraded for risk of bias: most information was at low or unclear risk of bias. Three studies had high risk of bias for
attrit ion, but the number of part icipants followed up was comparable between groups in the studies. We judged plausible bias
unlikely to alter the results.
kOne study reported the geometric mean, one study reported the log mean and one study reported the arithmetic mean; two
studies reported no ef fect of adding albendazole to DEC (P > 0.05).
lDowngraded by one for risk of bias: we judged the analyt ical methods used by Fox 2005 to obtain the change in density f rom
baseline to follow-up to be at high risk of bias.
mDowngraded by two for imprecision: the opt imal information size was not met. Two studies reported no ef fect of albendazole
added to DEC (P > 0.05). One study reported geometric mean, one study reported log mean and one study reported arithmetic
mean. Given the dif ferences in these measures and small number of part icipants, we are unable to judge the precision of the
est imate of ef fect across the studies.
nNot downgraded for risk of bias: all studies had unclear risk of bias for random sequence generat ion. The study contribut ing
the most (68.7%) to the ef fect est imate had high risk of bias for attrit ion, but the number of part icipants followed up was
comparable between groups. We judged plausible bias unlikely to seriously alter the results.
oDowngraded by one for indirectness: this outcome was assessed only in men and boys (three studies). Two studies included
adult men only, and one study included adults and children. We judged the evidence for this outcome to have serious
indirectness due to the lack of applicability to the wider populat ion of interest.
pDowngraded by one for imprecision: there were insuf f icient events to meet opt imal information size (47 total events). The
95% CI around the pooled est imate of ef fect includes both no ef fect and appreciable benef it and harm, using a relat ive risk
reduct ion (RRR) of 25%.
qNot downgraded for risk of bias: for part icipant and personnel blinding, one study had unclear risk of bias and one study was
at high risk of bias; however, a large safety study contribut ing the most to the overall ef fect est imate (73.1%) was at low risk
of bias. We judged plausible bias unlikely to seriously alter the results.
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Albendazole added to ivermectin for lymphatic filariasis
Patient or population: people with lymphatic f ilariasis or communit ies where lymphatic f ilariasis is endemic
Setting: Ghana, Hait i, Tanzania and Zanzibar
Intervention: albendazole plus ivermect in
Comparison: ivermect in
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with ivermectin Risk with albendazole
plus ivermectin
Microf ilaraemia (mf )
prevalence
follow-up: range 2
weeks to 12 months
129 per 1000 108 per 1000
(70 to 169)
RR 0.84
(0.54 to 1.31)
2519
(4 RCTs)
⊕⊕⊕©
MODERATEa,b,c
Due to imprecision
Albendazole probably
makes lit t le or no dif fer-
ence to mf prevalence
Mf density
follow-up: range 4
months to 6 months
No trend. The dif ference between the albenda-
zole plus ivermect in and the ivermect in groups
percentage reduct ions f rom baseline ranged
f rom a 3% to 22.8%greater reduct ion with alben-
dazole plus ivermect in.d
- 372
(3 RCTs)
⊕©©©
VERY LOWe,f,g
Due to risk of bias, incon-
sistency, and imprecision
We do not know if al-
bendazole has an ef fect
on mf density.
Mf density
follow-up: 12 months
Trend showed lit t le or no ef fect of albendazole.
The dif ference between the albendazole plus
ivermect in and the ivermect in groups percentage
reduct ions f rom baseline ranged f rom a 6.7%
to 9.1% greater reduct ion with albendazole plus
ivermect in.h
- 348
(2 RCTs)
⊕⊕©©
LOWi,j,k
Due to imprecision
Albendazole may make
lit t le or no dif ference to
mf density.
Ant igenaemia preva-
lence
follow up: 12 months
444 per 1000 462 per 1000
(418 to 516)
RR 1.04
(0.94 to 1.16)
1766
(2 RCTs)
⊕⊕⊕⊕
HIGHi
Albendazole makes lit -
t le or no dif ference
to ant igenaemia preva-
lence
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Antigen density
follow-up: 12 months
Trend showed lit t le or no ef fect of albendazole.
The dif ference between the albendazole plus
ivermect in and the ivermect in groups percentage
reduct ions f rom baseline ranged f rom a 10.9%
to 17.1%greater reduct ion with albendazole plus
ivermect in.h
- 733
(2 RCTs)
⊕⊕©©
LOWi,j,l
Due to imprecision
Albendazole may make
lit t le or no dif ference to
ant igen density
Adult worm prevalence
detected by ultrasound
- not measured
- - - - - Adult prevalence de-
tected by ultrasound
was not measured for
this comparison
Adverse events 122 per 1000 142 per 1000
(94 to 212)
RR 1.16
(0.77 to 1.74)
627
(1 RCT)
⊕⊕⊕©
MODERATEm,n
Due to imprecision
Albendazole probably
makes lit t le or no dif fer-
ence to adverse events
* The risk in the intervent ion group (and its 95% CI) is based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95%CI).
Abbreviat ions: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aNot downgraded for risk of bias: most information is f rom studies at low or unclear risk of bias. Two studies had high risk
and one had unclear risk of bias for attrit ion, but the number of part icipants followed up were comparable between groups
in most of the studies. We judged plausible bias unlikely to seriously alter the results.
bNot downgraded for inconsistency: although we found heterogeneity between studies (I2 = 65%), a subgroup analysis for
length of follow-up showed no stat ist ical variability when two studies with earlier follow-up t ime points (two weeks and four
months) and two studies with later follow-up t ime points (12 months) were analysed as subgroups. Overall, we judged that
the ef fect est imate is not inconsistent.
cDowngraded by one for imprecision: the opt imal information size was met. The 95%CI around the pooled est imate of ef fect
includes both no ef fect and appreciable benef it and harm, using a relat ive risk reduct ion (RRR) of 25%.
dOne small study reported an ef fect of adding albendazole to ivermect in (P < 0.05), one study reported no ef fect (P > 0.05),
and one study did not clearly report the outcome of the stat ist ical analyses.
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eDowngraded by one for risk of bias: we judged the analyt ical methods used by Beach 1999 to obtain the change in density
f rom baseline to follow-up to be at high risk of bias.
fDowngraded by one for inconsistency: the magnitude of the ef fect of adding albendazole to ivermect in varied and we judged
it to be inconsistent.
gDowngraded by two for imprecision: the opt imal information size was not met. The ef fect of adding albendazole to ivermect in
showed considerable variability; ranging f rom an ef fect in one study (P < 0.05) and lit t le or no ef fect (P > 0.05) in another. We
judged that the range of values could include a meaningful ef fect and no ef fect.
hOne study reported no ef fect of adding albendazole to ivermect in (P > 0.05), and one study did not clearly report the outcome
of the stat ist ical analyses.
iNot downgraded for risk of bias: most information is f rom studies at low or unclear risk of bias. Two studies had high risk
or unclear risk of bias for attrit ion, but losses between groups were generally comparable in the studies. We judged plausible
bias unlikely to seriously alter the results.
jNot downgraded for inconsistency: we judged the direct ion and magnitude of ef fect to be consistent across studies.
kDowngraded by two for imprecision: the opt imal information size was not met. Two studies reported lit t le or no ef fect with
albendazole; stat ist ically evaluated in one study (P > 0.05). We judged that the range of values would likely include lit t le or
no ef fect and exclude appreciable benef it or harm, but we can not be certain as there is no est imate of ef fect or measure of
precision.
lDowngraded by two for imprecision: the opt imal information size was met. Two studies reported lit t le or no ef fect of
albendazole; stat ist ically evaluated in one study (P > 0.05). We judged that the range of values would likely include lit t le or
no ef fect and exclude appreciable benef it or harm, but we can not be certain as there is no est imate of ef fect or measure of
precision.
mNot downgraded for risk of bias: most information was at low and unclear risk of bias. The study had unclear risk of bias
for part icipant and personnel blinding and unclear risk of bias for attrit ion. However, for this outcome 90%of individuals were
followed up. We judged plausible bias unlikely to seriously alter the results.
nDowngraded by one for imprecision: insuf f icient events to meet opt imal information size (83 total events). The 95%CI around
the pooled est imate of ef fect includes both no ef fect and appreciable harm, using a 25% relat ive risk reduct ion (RRR).
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D I S C U S S I O N
Summary of main results
Albendazole given alone or added to a microfilaricidal drug makes
little or no difference to mf prevalence over two weeks to 12
months post-treatment (high-certainty evidence), but we do not
know if there is an effect on mf density over one to six months
(very-low certainty evidence), or at 12 months follow-up (very
low-certainty evidence). For antigenaemia prevalence between six
to 12 months, albendazole alone or in combination makes little or
no difference (high-certainty evidence). For antigen density over
six to 12 months, we do not know if albendazole has an effect
(very low-certainty evidence). For adult worm prevalence detected
by ultrasound at 12 months, albendazole may make little or no
difference (low-certainty evidence). Albendazole alone or added
to a microfilaricidal drug makes little or no difference to adverse
events (high-certainty evidence). See Summary of findings for the
main comparison.
Albendazole given alone makes little or no difference to mf preva-
lence over four to 12 months post-treatment (high-certainty evi-
dence), but we do not know if there is an effect on mf density after
four to six months (very low-certainty evidence), or at 12 months
follow-up (very low-certainty evidence). For antigenaemia preva-
lence over six to 12 months post-treatment, albendazole makes lit-
tle or no difference (high-certainty evidence). For antigen density
over six to 12 months, we do not know if albendazole has an effect
(very low-certainty evidence). For adult worm prevalence detected
by ultrasound, the effect of albendazole was not measured. Al-
bendazole probably makes little or no difference to adverse events
(moderate-certainty evidence). See Summary of findings 2.
Albendazole added to DEC probably makes little or no difference
to mf prevalence over six to 12 months post-treatment (moderate-
certainty evidence). For mf density between one to six months,
we do not know if there is an effect (very low-certainty evidence),
but albendazole co-administered with DEC may make little or no
difference to mf density at 12 months (low-certainty evidence).
For antigenaemia prevalence between six to 12 months post-treat-
ment, albendazole makes little or no difference (high-certainty ev-
idence). For antigen density over six to 12 months, we do not
know if albendazole has an effect (very low-certainty evidence).
For adult worm prevalence detected by ultrasound at 12 months,
albendazole plus DEC may make little or no difference (low-cer-
tainty evidence). Albendazole added toDECmakes little or no dif-
ference to adverse events (high-certainty evidence). See Summary
of findings 3.
Albendazole added to ivermectin probably makes little or no dif-
ference to mf prevalence over two weeks to 12 months post-treat-
ment (moderate-certainty evidence). For mf density between four
to six months, we do not know if there is an effect (very low-
certainty evidence), but albendazole co-administered with iver-
mectin may make little or no difference at 12 months (low-cer-
tainty evidence). For antigenaemia prevalence at 12 months, al-
bendazole makes little or no difference (high-certainty evidence).
For antigen density at 12 months, the albendazole plus ivermectin
combination may make little or no difference (low-certainty ev-
idence). For adult worm prevalence detected by ultrasound, the
effect of albendazole plus ivermectin versus ivermectin was not
measured. Albendazole added to ivermectin probably makes little
or no difference to adverse events (moderate-certainty evidence).
See Summary of findings 4.
Overall completeness and applicability of
evidence
Measures of transmission potential
In people with lymphatic filariasis and people from lymphatic
filariasis-endemic communities, treatment with albendazole alone
or albendazole added to antifilarial drugs, DEC or ivermectin, had
little or no effect on mf prevalence. All trials included in the review
assessed mf prevalence, and the evidence for the lack of effect
comes from trials that were conducted in a variety of locations and
settings, included both adults and children, and included both
infected and uninfected individuals.
The trials used a range of methods to measure and calculate
changes in mf density, and the reported efficacy of albendazole
given alone or in combination with a microfilaricidal drug ranged
from showing an effect to no effect, with greater inconsistency seen
up to six months post-treatment. All trials measured mf density,
but trial authors mainly reported the results of small subgroups of
microfilaraemic individuals at follow-up, rather than all random-
ized individuals. The benefit of albendazole regimens when given
to endemic communities could not be assessed.
No trials included in the review assessed treatment twice per year
with albendazole, so we could not determine whether the WHO
recommendation for albendazole alone twice per year to treat
lymphatic filariasis in loiasis-endemic areas is supported (WHO
2012). Other studies have reported a benefit of an increased dose
or frequency of albendazole for individual treatment and commu-
nity control, but these were either not placebo-controlled trials
(Pion 2015), or were not designed to assess the effects of albenda-
zole alone (Kar 2015; Tafatatha 2015).
Markers of adult worm infection
Albendazole is thought to have some macrofilaricidal properties
when given at high doses over several weeks (Jayakody 1993).
However, a single 400 mg dose of albendazole (the dose used in
MDA programmes), given either as monotherapy or as a combi-
nation therapy, had little or no effect on adult worm prevalence
after six to 12 months.
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Evidence for an overall effect of albendazole for reducing adult
worm viability was limited to comparing the antigen density re-
ductions and the trial authors’ statistical interpretation, but no
studies reported a significant effect (P < 0.05) of albendazole alone
or when added to a microfilaricidal drug. The trials were individu-
ally-randomized and primarily assessed subgroups of antigenaemic
individuals, and so we could not evaluate the effect of albendazole
on CFA density at the community level.
Three trials also assessed adult worm (filarial dance sign) preva-
lence using ultrasound with male participants treated with alben-
dazole co-administered withDEC orDEC alone. The limited cur-
rent evidence suggests that albendazole may give little or no addi-
tional benefit over DEC alone. One trial included in this review
reported that the addition of albendazole appeared to decrease the
macrofilaricidal effect of DEC against W bancrofti (Dreyer 2006).
However, these trials were small and so we can not completely rule
out any macrofilaricidal effect.
Clinical disease
The effect of albendazole, either alone orwhen added to ivermectin
for clinical disease, was not remarkable. This is not surprising
as effect sizes for clinical outcomes were small and the one trial
that assessed this was not powered to detect small clinical benefits
(Dunyo 2000).
Adverse events
Nearly all trials reported on adverse events, with treatment with
albendazole alone or combined with ivermectin or DEC making
little difference to adverse events in people with lymphatic filar-
iasis or in people in endemic communities. Adverse events were
generally mild and systemic. Local adverse events were reported in
two small trials that compared albendazole co-administered with
DEC to DEC alone (Dreyer 2006; Rizzo 2007). Rizzo 2007 ob-
served no difference between groups, but Dreyer 2006 detected
a higher proportion of “sensitive reactions” in men in the DEC
group compared to men given the albendazole and DEC combi-
nation. There do not appear to be safety concerns for albendazole
when given at the dose or in the drug combinations recommended
for lymphatic filariasis MDA programmes (WHO 2006).
Long-term effects
Multiple rounds of annual treatment with albendazole and either
DEC or ivermectin are recommended in lymphatic filariasis elimi-
nation programmes in order to sustainably interrupt transmission.
There is insufficient evidence to draw any meaningful conclusions
on the long-term impact of albendazole for lymphatic filariasis.
The impact of albendazole on outcomes in the long term (at 24 or
36 months post-treatment) was evaluated in four trials that com-
pared albendazole added to DEC with DEC alone.
In a small subgroup of randomized participants, Kshirsagar 2004
reported that there was no effect of adding albendazole for any of
the parasitological outcomes measured after three annual rounds
of treatment. Pani 2002 and Bockarie 2007 showed little or no
effect of adding albendazole for parasitological outcomes at 24 or
36 months after a single dose of the treatments; and Pani 2002,
a very small trial, reported a greater increase in antigen density
at 36 months post-treatment with the albendazole combination
therapy.
Certainty of the evidence
Thirteen trials, including one cluster-RCT, with 8713 participants
met the inclusion criteria.We assessed the certainty of the evidence
for mf prevalence and antigenaemia prevalence outcomes as high
for our main analysis, albendazole alone or added to a microfilar-
icidal drug. In individual comparisons, we graded the certainty of
the evidence for mf prevalence as high for albendazole alone, and
moderate for albendazole added toDEC and albendazole added to
ivermectin. The other parasitological outcomes, mf density, anti-
gen density, and adult worm prevalence detected by ultrasound,
had low or very low certainty evidence for an effect of albendazole.
All trials were described as randomized, but they had important
limitations. Most included studies were designed primarily to as-
sess the effectiveness of albendazole for treatment of individuals,
and did not explicitly consider the effects on transmission in whole
communities. The numbers of participants lost to or excluded
from the follow-up were also very high (above 20%) in almost half
of the trials, which could lead to imbalances in the comparison
groups. However, the numbers lost were generally comparable be-
tween treatment groups within the trials.
Differences in design (mf-positive participants only compared to
positive and negative participants, variable outcome measurement
and reporting, and follow-up times) made it difficult to compare
the trials.Most trials reported outcomesmainly for those whowere
mf-positive or antigen-positive at baseline. Selectively analysing
subgroups of randomized participants may bias the conclusions of
the study, and result in an overestimation or dilution of potential
treatment effects.
For parasite density data, the difference in outcome summarymea-
sure reported (i.e. geometric mean, arithmetic mean, log mean),
the analysis methods used, and the lack of reporting of SDs or
CIs in most trials made it impossible to include these results in a
meta-analysis. Studies should report measures of variance or CIs
so that the amount of uncertainty in the point estimate is clear.
We judged the analytical methods used by some trials to be at high
risk of bias due to the method used to calculate the change from
baseline (Beach 1999; Fox 2005), or use of the arithmetic mean as
the average estimate. For studies that reported no transformation
onto the log scale for skewness in the data, using the arithmetic
mean tomeasure skewed data is not appropriate. Tests of statistical
significance were also not always carried out or reported. For these
reasons, we downgraded the certainty of the evidence for density
outcomes by two levels for imprecision; by one for risk of bias
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when data from Beach 1999 or Fox 2005 were included; and by
one when there was also inconsistency between trials.
Potential biases in the review process
Statistical errors in analysis
We included one cluster-RCT in the review (Wamae 2011), but
the trial authors did not take adequate account of cluster random-
ization. The analyses for primary and secondary outcomes were
not adjusted for clustering, and the trial authors reported results
from subgroups of microfilaraemic and antigenaemic individuals.
This could impact the interpretation of the trial, and we did not
use these data in our analyses. However, we have reported all rel-
evant outcomes not included in our analyses in Appendix 2.
Parasite density outcomes
Due to the poor reporting of parasite density outcomes we could
not combine trials in a meta-analysis. We attempted to contact
several trial authors to clarify their methods or request CIs for
the data (Beach 1999; Simonsen 2004; Fox 2005; Dreyer 2006;
Bockarie 2007; Rizzo 2007; De Britto 2015). We received a re-
sponse from Dreyer 2006 and Rizzo 2007, and are awaiting data
from Beach 1999. We could not find an active email address for
Simonsen 2004.
We therefore analysed density data by comparing the difference
in percentage reduction between the intervention and control
groups, with less weighting given to trials that reported the mean
(as this does not account for potentially skewed data). We also
considered the results of the statistical analyses reported by the
authors. This could introduce bias, as authors assessed subgroups
of the total randomized individuals and calculated the geometric
mean and percentage reduction in geometric mean using different
methods. Tests of statistical significance were not always carried
out or reported. However, we judged the evidence to be low to
very low certainty.
Subgroup analyses
Many of the included trials had several dissimilar follow-up inter-
vals and reported on subgroups of participants for the outcomes.
We analysed the longest follow-up up to 12 months from each
trial, and used the number randomized as the denominator where
possible. This meant combining trials that analysed individuals
who were all microfilaraemic or positive for adult worms with tri-
als that analysed infected and uninfected individuals. We believed
this would not bias the findings of our review.
We did detect moderate heterogeneity when comparing albenda-
zole plus ivermectin to ivermectin alone formf prevalence, but this
appeared to be explained by trial follow-up periods, which ranged
from two weeks to 12 months.
We also conducted additional meta-analyses to assess different
follow-up times (up to six, and at 12, 24 and 36 months), and
stratified the analyses by the participants’ baseline infection status
to rule out any potential time-dependent effects or other specific
effects of albendazole. The number of participants in the subgroup
analyses were generally small, but the results of these additional
meta-analyses were in broad agreement with our primary analyses
assessing the longest follow-up data.
Agreements and disagreements with other
studies or reviews
The findings from our review are in agreement with the findings
from a literature review published in 2005, Tisch 2005, which
conducted a systematic evaluation of data from publicly available
drug trials to determine estimates of drug effect againstW bancrofti
mf in individuals and populations. Tisch 2005 concluded that the
use of albendazole with a microfilaricidal drug does not appear to
augment the effectiveness of a single microfilaricidal drug, and the
authors also emphasized the need for further research and clearer
reporting of trials. However, the methods of this literature review
differed from our Cochrane Review: it was not a protocol-driven
systematic review; effect estimates and precision around the effect
estimate for outcomes were not determined using meta-analyses;
and the study quality was not assessed for included studies.
The findings of our review are at odds with the original docu-
ments that led to the introduction of albendazole to filarial con-
trol programmes, including a WHO consultation on albendazole
research findings in lymphatic filariasis (WHO 1998) and a nar-
rative review (Ottesen 1999). The narrative review conducted by
theWHO concluded that “single dose 2-drug combinations of al-
bendazole plus either ivermectin orDEC are superior in efficacy to
single drug treatment for decreasing microfilaraemia in lymphatic
filariasis”, and that “Albendazole alone has a killing or sterilizing
activity on lymphatic filarial adult worms” (WHO 1998).
An expert opinion review and meta-analysis by Gyapong 2005
favoured the two-drug regimens over single microfilaricidal drugs
for treating and preventing lymphatic filariasis. Their analyses dif-
fer from our analyses in a number of ways: it was not a proto-
col-driven systematic review; the authors included scientific liter-
ature supplemented by reports and studies, and did not assess the
quality of the studies; the authors only included studies where the
participants were microfilaraemic; the statistical significance may
also have been overstated in some analyses, since data from several
studies were incorporated twice (by counting results at six and 12
months and combining them in the same meta-analysis), which
artificially narrows the 95% CIs.
A narrative literature review by Olsen 2007 presented evidence
reported by individual studies, and concluded: “Results with ALB
added to single-drug therapywith IVM orDEC against lymphatic
filariasis were inconclusive, but DEC and IVM in combination
appeared to be superior to DEC or IVM alone.” Their analyses
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differ from ours, in that: it was not a protocol-driven systematic
review; it was a narrative summary of studies rather than a meta-
analysis of data; and the study quality was not assessed for included
studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is good evidence from individually-randomized trials that
albendazole has little or no effect on completely clearing the mf
or adult worms up to 12 months after treatment, and no convinc-
ing data across studies of an effect on mf density or adult worm
viability. This finding is consistent in studies evaluating albenda-
zole alone, or studies where albendazole is added to DEC or iver-
mectin- two drugs known to be effective in community treatment
programmes.
If there is a true but as yet unproven effect on parasite density, then
it is possible that albendazole could have an effect on transmission
in mass treatment programmes. There are no large cluster-ran-
domized studies to determine whether there is a population-level
effect, although these were called for in the initial WHO informal
consultation in 1998 (WHO 1998).
This review, and the earlier editions, raise fundamental questions
around the evidence base of the effectiveness of albendazole and
thus its inclusion in the global lymphatic filariasis elimination pro-
gramme. Given that the drug is part of mainstream policy, and the
WHOnow recommend the triple-drug regimen IDA (ivermectin,
DEC, and albendazole), we are unlikely to see new research eval-
uating albendazole in combination with DEC or ivermectin.
However, albendazole alone is recommended in areas endemic for
L loa. In our view, this remains a priority for research through
placebo-controlled trials to know whether the drug is effective in
these communities.
Implications for research
The key area that needs elucidation is whether albendazole has an
independent effect on mf density, to guide treatment decisions for
lymphatic filariasis in L loa-endemic areas.
Re-analysis of the existing parasite density data as part of an in-
dividual patient data meta-analysis would be theoretically help-
ful, but we have sought the data without success, and this does
not look feasible. Future study authors should consider depositing
their data and analyses in community-recognized repositories, to
make it possible to reproduce results and facilitate meta-analysis.
In further research, it would help if there were better standardiza-
tion in field and analytical methods. Techniques for assessing mf
in blood and outcome measures for mf densities should also be
standardized, with complete reporting of all randomized individ-
uals. The synthesis of data for mf density in this review proved
to be challenging. In many studies, the authors applied log trans-
formations to the data to be able to calculate geometric means,
since data were skewed. It was not possible to meta-analyse data
for this outcome due to poor reporting of methods of analysis and
results in the individual study reports. Firstly, many studies de-
scribed methods to accommodate zero values (such as adding 1 to
each value before taking the log of each value), but these methods
were often not sufficiently detailed and referenced. Study authors
should describe exactly how the method was applied (i.e. to all
values or to zero values only), and exactly what summary measures
are presented (i.e. geometric means, log means) and how these
were calculated.
For example, Simonsen 2004 reports that “geometric mean inten-
sities (mf GMIs) were calculated as antilog[( log x + 1))/n] - 1”; this
is perfectly sufficient detail, but many studies’ methods were not
so clear. Secondly, several studies reported only the point estimates
of the geometric mean, or the log mean, without any measure of
variance or CIs. Studies should report measures of variance or CIs
so that the amount of uncertainty in the estimate is clear; this
would also enable study results to be included in meta-analyses.
Finally, some studies reported no transformation onto the log scale
for skewness in the data; if data were skewed then summarizing
using arithmetic means is not appropriate, and it then becomes
impossible to combine studies which report arithmeticmeans with
studies that report geometric or log means.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beach 1999
Methods RCT
Study dates: January 1996 to May 1996
Length of follow-up: 4 months
Method of microfilariae (mf) assessment/volume of blood: thick smear, 20 µL of finger-
prick blood collected between 7pm and 9.30pm
Method of adverse event assessment: schools were revisited for 3 - 5 days after treatment
to systematicallymeasure adverse reactions in themicrofilaraemic children and to provide
medical consultation to other children. Adverse event severity was graded and a total-
peak intensity score calculated
Participants All children attending 5 selected primary schools
Number analysed for primary outcome: 585 participants of 965 participants randomized
Mean age (years): 7.4
Inclusion criteria: 1) age 5 to 11 years; 2) anthropometric measurements before and
4 months after treatment; 3) stool specimens before and 5 weeks after treatment; 4)
random assignment to a treatment group; 5) height, weight, and age within limits of the
anthropometric database
Interventions Single dose
1. Albendazole: 400 mg, 244 participants
2. Ivermectin: 200 to 400 µg/kg, 240 participants
3. Albendazole plus ivermectin: same dose as above, 245 participants
4. Placebo: 250 mg vitamin C, 229 participants
Outcomes For all children
1. Mf prevalence post-treatment
2. Change in mf prevalence post-treatment (albendazole excluded from statistical
analyses)
For mf-positive children only
1. Mf prevalence post-treatment
2. Change in mf prevalence post-treatment
3. Median (range) mf concentration post-treatment
4. Median percentage reduction in mf concentration post-treatment
5. Geometric mean mf concentration post-treatment
6. Geometric mean percentage reduction in mf concentration post-treatment
7. Frequency of the occurrence of specific systemic adverse events, such as fever,
headache, weakness, muscle/joint pain, itching, rash, abdominal pain, and diarrhoea
post-treatment
8. Grading of adverse event severity and calculation of mean severe score (range) and
total peak intensity score
Not included in review:
Intestinal helminth prevalence and intensity; reduction in intensity of geohelminth in-
fections reported as geometric means, as defined by egg count (eggs/gram of stool [epg]);
anthropometric measurements of height and weight measurements; a stool examination
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Beach 1999 (Continued)
for intestinal helminths; hematocrit measurements
Notes Study type: school-based
Location: Leogane, Haiti
Medication supervised: children took the medication under direct investigator observa-
tion
Source of funding: USAID
Endemicity level: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “For each school, all eligible stu-
dents were assigned, using a random num-
ber table, to four treatment groups”
Allocation concealment (selection bias) Low risk Quote: “Treatment was given... by one of
the investigators from Centers for Disease
Control and Prevention, where the code for
allocation was kept. The code was broken
at the end of the second follow-up.”
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Low risk Quote: “personnel evaluating students for
adverse reactions were blinded to the treat-
ment status of the children”
Quote: “double blind”.
Comment: although drugs were not identi-
cal, patients hadnoway of identifying them
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Low risk Quote: “Laboratory personnel, measure-
ment teams… were blinded to the treat-
ment status of the children.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 585/965 (61%) of randomized
participants were evaluated for primary
outcome. Reason for losses to follow-up
were reported as exclusion of childrenwith-
out both pre- and post-treatment blood
samples from analyses. Inclusion of all ran-
domized participants (number evaluable/
number randomized): 61% (585/965)
Selective reporting (reporting bias) Unclear risk Comment: authors stated in the meth-
ods: “Adverse reactions included headache,
fever, myalgias, abdominal pain, passage of
worms in the stool, vomiting, diarrhoea,
cough, and dyspnoea”
Author did not report on dizziness, weak-
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Beach 1999 (Continued)
ness, or abdominal pain
Other bias Unclear risk Comment: risk of bias for mf density is
unclear, as before estimating the percent-
age reduction between baseline and follow-
up, the authors omitted increases in den-
sity. This study simply provides an assess-
ment of the decrease in density only in peo-
ple experiencing a decrease.Whilst this rule
was applied to both intervention and con-
trol groups, we were uncertain of the effect
of this on the estimate, or exactly what the
estimate was measuring
Bockarie 2007
Methods RCT
Study dates: September 1999 to September 2001
Length of follow-up: 24 months
Method ofmf assessment/volume of blood: lightmicroscopy afterNuclepore®filtration,
1 mL venous blood collected between 10pm and 2am
Antigen testing: Og4C3 antigen ELISA
Participants All adults and children living in an endemic area
Number analysed for primary outcome: 729 participants of 1007 participants random-
ized (at 24 month final follow-up only)
Mean age (years): 23.4 (DEC) and 24.7 (DEC plus albendazole)
Inclusion criteria: all residents > 2 years of age
Exclusion criteria: pregnant women
Interventions Single dose
1. DEC: 6 mg/kg, 497 participants
2. DEC plus albendazole: 6 mg/kg plus 400 mg, 510 participants
Outcomes For all individuals and the subset of individuals antigen-positive at baseline
Measured:
1. Mf prevalence post-treatment
2. Change in mf prevalence post-treatment
3. Geometric mean mf density post-treatment
4. Change in geometric mean mf density post-treatment
5. Antigenaemia prevalence post-treatment
6. Change in antigenaemia prevalence post-treatment
7. Antigenemia density post-treatment
8. Change in antigenaemia density post-treatment
Reported:
Outcomes were analysed for different subsets of participants based on availability of sam-
ples at different time points or pre-treatment parasitological status; however, outcomes
were not fully reported for some subsets of individuals or for the time points surveyed
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Bockarie 2007 (Continued)
Notes Study type: community-based
Location: all 3 villages on Bagabag Island, northeast of Madang in Madang Province,
Papua New Guinea
Source of funding: WHO/CTD grant and WHO grant
Medication supervised: witnessed drug administration
Endemicity level: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “assigned randomly”
Comment: Not clear how sequence was
generated
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Unclear risk No details reported
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Unclear risk No details reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 729/1007 (72.4%) of random-
ized participants were evaluated for pri-
mary outcome. Losses to follow-up were
attributed to the availability of participant
samples at different time points. Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 72.4%
(729/1007)
There were high losses to follow-up for
other outcome analyses: 245/527 (46.
5%) of randomized antigen-positive par-
ticipants were evaluated at 6, 12 and 24
months for mf outcomes, and months 6
and 12 for antigenaemia outcomes; 271/
1007 (26.9%) of randomized participants
were evaluated (different individuals from
other analysis) for antigenaemia outcomes
at 24 months
Selective reporting (reporting bias) High risk Authors stated in the methods: “The MF
and Og4C3 levels intensities were com-
pared between treatment groups and across
follow-up periods...”
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Bockarie 2007 (Continued)
Comment: Antigen density data were mea-
sured at 6 and 12 months, but only re-
ported at 24 months follow-up in a small
subset of participants; the intervention was
favoured at this time
Other bias Low risk No other obvious source of bias
Dahoma 2000
Methods RCT
Study dates: November 1999 to February 2000
Length of follow-up: 2 weeks
Method of mf assessment/volume of blood: counting chamber technique, 200µL finger-
prick blood collected between 10pm and 3am, and between 10pm and 12pm at follow-
up
Method of adverse event assessment: Side effects and their types were determined by
follow-up and close monitoring for development of adverse signs and symptoms up to
96 hours post-treatment
Participants All individuals living in 2 endemic areas
Number analysed for primary outcome: 407 participants of 418 participants randomized
(97.4%)
Age range/mean age: not reported
Inclusion criteria: Individuals > 2 years of age with microfilaraemia or clinically active
disease
Exclusion criteria: Sick, pregnant, history of allergy to treatment drugs
Interventions Single dose
1. Albendazole plus ivermectin: dose unknown, 202 participants
2. Placebo plus ivermectin: dose unknown, 205 participants
Outcomes 1. Mf prevalence post-treatment
2. Percentage reduction in mf prevalence post-treatment
3. Type and proportion of common side effects reported relative to baseline
Not included in review:
Community screening data; reduction (%) in mf post-treatment by age and sex; per-
centage reduction in mf intensity post-treatment stratified by 3 intensity categories;
symptoms reported post-treatment with a prevalence 1 - 3.9%; significance of change in
proportion of reported symptoms with values greater than 4% prevalence; measurement
of pulse, respiratory, systolic and diastolic blood pressure in individuals over 12; preva-
lence, intensity and reduction in geohelminth infection post-treatment (by age and sex)
; prevalence of co-infection of LF with geohelminths
Notes Study type: community-based
Location: Unguja Island, Zanzibar
Source of funding: author sponsored by MOH-Zanzibar and WHO Tanzania office
Medication supervised: not reported
Endemicity level: 13.7% in the south district
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Dahoma 2000 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants allocation to treat-
ment arms was done by tossing a coin.”
Allocation concealment (selection bias) Low risk Quote: “Since the drugs were received un-
randomized, drug randomisation had to be
done locally basing on patient weight....
This procedure was done by an experienced
clinical officer and drugs were coded.”
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Unclear risk Quote: “Double blind”
Comment: unclear if the placebo and al-
bendazole were identical, but participants
likely had no way of identifying them
Unclear how personnel were blinded
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Low risk Quote: “Drug codes were broken when
post-treatment when parasitological exam-
ination was completed.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 407/418 (97.4%) of random-
ized participants were evaluated for pri-
mary outcome.Reasons for losses to follow-
up were reported. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 97.4% (407/418)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No obvious other source of bias
De Britto 2015
Methods RCT
Study dates: not reported
Length of follow-up: 12 months
Method of mf assessment/volume of blood: membrane filtration (with 5 micron mem-
brane filter, Millipore, type TMTP) and examination of stained filters by microscopy, 1
mL venous blood collected between 8pm and 10pm
Antigen testing: Og4C3 ELISA and Immunochromatographic card test (ICT)
Method of adverse event assessment: clinical nurse visited the study participants every
day to record the symptoms of adverse reactions
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De Britto 2015 (Continued)
Participants Microfilaraemic individuals identified by screening
Number analysed for primary outcome: 64 participants of 75 participants randomized
in the DEC treatment group and the DEC plus albendazole treatment group
Mean age (years): 36.1 (DEC) and 35.8 (DEC plus albendazole)
Inclusion criteria: adults with night blood microfilaria counts > 10 mf/mL
Exclusion criteria: body weight < 30 kg, filariasis treatment in previous 2 years or de-
worming treatment in previous year, concurrent illness, psychiatric disorders and patients
under rifampicin, minocycline or doxycycline therapy Pregnant women and lactating
mothers
Interventions Multiple doses
1. DEC: 300 mg/day for 12 days, followed by placebo for 12 days, 36 participants
2. DEC plus albendazole: 300 mg/day plus 400mg/day for 12 days, followed by
placebo for 12 days, 39 participants
3. DEC plus doxycycline: 300 mg/day plus 100 mg/day for 12 days, followed by
placebo for 12 days, 38 participants
4. DEC plus albendazole sequential treatment: DEC for 12 days, and DEC plus
albendazole sequentially for 12 days 30 days after initiating DEC therapy, 33
participants
Outcomes 1. Mf prevalence post-treatment (percentage clearance reported graphically at 26
and 52 weeks)
2. Change in mf prevalence post-treatment (percentage mf clearance reported
graphically at 26 and 52 weeks)
3. Mean mf density (log) post-treatment
4. Change in mean mf density (log) post-treatment
5. Mean antigen level (log) post-treatment
6. Change in mean antigen level (log) post-treatment
7. Antigen prevalence post-treatment
8. Change in antigen prevalence post-treatment
9. Prevalence of adverse reaction symptoms after 1st treatment round and 2nd
placebo treatment round
10. Duration of side reactions stratified by number of days
Note: SD reported only for baseline mean (log) mf count and mean (log) antigen units,
but not at follow-up
Notes Study type: community-based
Location: 35 endemic villages of Vector Control Research Centre (VCRC) field practice
areas in Pondicherry and Tamil Nadu regions, South India
Source of funding: Indian Council of Medical Research (ICMR), Department of Health
Research, Government of India
Medication supervised: not reported
Endemicity level: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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De Britto 2015 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “All eligible participants were di-
vided into blocks of size four and within
each block, individual randomization irre-
spective of the gender and blood microfi-
laria count was done to have almost equal
number of participants in each regimen.”
Comment: unclear how sequence was gen-
erated
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Unclear risk Quote: “double-blind”.
Comment: placebo used for 2nd treatment
pulse in 3 of 4 treatment groups, unlikely
participants knew which treatment they
were given
Unclear how personnel were blinded
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: inclusionof all randomizedpar-
ticipants (number evaluable/number ran-
domized): 88.4% (129/146)
85.3% (64/75) of randomized participants
in theDEC treatment group andDECplus
albendazole treatment group were evalu-
ated. Reasons for loss to follow-up re-
ported, and there was similar attrition be-
tween 2 treatment groups. Inclusion of all
randomized participants (number evalu-
able/number randomized): 85.3% (64/75)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Comment: mf clearance at 26 weeks and
52 weeks reported graphically
Other bias Low risk No obvious other source of bias
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Dreyer 2006
Methods RCT
Study dates: not reported
Length of follow-up: 12 months
Method of mf assessment/volume of blood: membrane filtration (3 µm Nucleopore
filter, Nuclepore Corporation, Pleasanton, CA, USA) and microscopy of stained filter, 1
mL venous blood collected at night
Method of macrofilariae viability assessment: physical and ultrasound examinations of
the scrotal area to identify intrascrotal nodules and filaria dance sign (FDS). Ultrasound
examinations involved a portable ALOKA SSD-500 (Japan) or a portable Pie Medical
200 (The Netherlands) ultrasound machine, both equipped with a 7.5 mHz probe.
Physical andultrasound examinations of the lymphatic vessels and lymphnodes elsewhere
in the body were also performed
Participants Adult men with FDS identified by screening
Number analysed for primary outcome: 46 participants of 47 participants randomized
Mean age (years): 21.5 (DEC) and 29.4 (DEC plus albendazole)
Inclusion criteria: (1) over 18 years of age; (2) reproducible FDS confirmed by 2 inde-
pendent investigators on 3 separate occasions pre-treatment; (3) no hydrocoele or genital
lymphoedema; (4) no history of DEC or ivermectin treatment; (5) no anthelminthic
drugs post-treatment; (6) adhered to follow-up schedule
Interventions Single dose
1. DEC: 6 mg/kg, 25 participants
2. DEC plus albendazole: 6 mg/kg plus 400 mg, 22 participants
Outcomes 1. Detection of mixed, sensitive or non-sensitive reactions assessed by physical and
ultrasound examinations post-treatment
2. Number of new nodules detected during follow-up
3. Number of new living adult worm nests detected during follow-up
4. Mf prevalence post-treatment
5. Change in mf prevalence post-treatment
6. Geometric mean mf density
7. Change in geometric mean mf density post-treatment
8. Examination of the lymphatic vessels and lymph nodes in the body
(Note: the raw data files were obtained from the authors on request)
Notes Study type: hospital-based
Location: outpatient clinic of NEPAF, Hospital das Clínicas, Federal University of Per-
nambuco, Recife, Brazil
Source of funding: Amaury Coutinho Non-Governmental Organization, Recife, Brazil
Medication supervised: treated under direct observation
Endemicity level: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Dreyer 2006 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “The men were randomly assigned
to a treatment group”
Comment: unclear how sequence was gen-
erated
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Unclear risk Comment: unclear whether assessors
counting mf were blinded.
Physical examinations were blinded, but
there may be insufficient blinding of ultra-
sound examinations:
Quote: “The physician performing the
physical examinations (J.N.) was unaware
of the subject’s treatment status or ultra-
sound findings.”
Quote: “Two sonographers independently
performedultrasound examinations; one of
these examiners remained blinded both to
treatment status and physical examination
results throughout the study.”
Quote: “The two sonographers agreed on
ultrasound findings for all study subjects.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 97.9% (46/47) of randomized
participants were evaluated. Reasons for
losses to follow-up were reported. Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 97.9%
(46/47)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk Comment: men who were treated with
DEC alone were significantly younger
(mean age, 21.5 years) than those who re-
ceived both drugs (mean, 29.4 years)
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Dunyo 2000
Methods RCT
Sudy dates: October 1996 to July 1998
Length of follow-up: 12 months
Method of mf assessment/volume of blood: counting chamber technique, 100 µL of
fingerprick blood collected at night from 9pm
Antigen testing: ELISA testing using fingerprick blood specimens
Method of clinical disease assessment: Individuals were clinically examined during the
day for evidence of elephantiasis and hydrocoele. Limb lymphoedema and hydrocoele
were graded
Method of adverse event assessment: treated individuals were monitored for 5 days to
record self-reported adverse reactions using a check-list. Reaction severity was graded as 0
=none; 1 =mild (noticeable to the participant but not interferingwith daily activities); 2 =
moderate (some interference with daily activities); and 3 = severe (complete interruption
of daily activities), and for 1 year to report any long-term untoward events
Participants All individuals living in 4 endemic areas
Number analysed for primary outcome: 1181 participants of 1425 participants random-
ized
Mean age: 26.4
Exclusion criteria: children aged < 6 years and pregnant women
Interventions Single dose
1. Albendazole: 400 mg, 369 participants
2. Ivermectin: 150 to 200 µg/kg, 336 participants
3. Albendazole plus ivermectin: same as above, 370 participants
4. Placebo: 350 participants
Outcomes 1. Mf prevalence post-treatment
2. Change in mf prevalence post-treatment
3. Geometric mean mf density (time-adjusted and unadjusted)
4. Change in geometric mean mf density
5. Geometric mean circulating filarial antigen (CFA) density post-treatment
6. Change in geometric mean CFA density post-treatment
7. New cases of microfilaraemia post-treatment and geometric mean mf intensity
8. New cases of antigenaemia post-treatment and geometric mean CFA intensity
9. Reduction in grade or disappearance of clinical disease (lymphoedema or
hydrocoele) post-treatment
10. Increase in clinical disease grade (lymphoedema or hydrocoele) post-treatment
11. Appearance of new clinical disease (lymphoedema or hydrocoele) post-treatment
12. Frequency of specific systemic adverse events as well as the number of individuals
presenting with any adverse event post-treatment
Not included in review: mortality during follow-up
(Note: standard deviation (SD) for geometric mean density data was not reported. 95%
CIs for geometric mean mf intensity were reported only for individuals who had≥ 100
mf/mL before treatment and who were also examined at 12 months after treatment)
Notes Study type: community-based
Location: south-western Ghana (Butre, Achowa, Adjan, and Miamia villages)
Source of funding: Danish Bilharziasis Laboratory, Denmark
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Dunyo 2000 (Continued)
Medication supervised: treatment administered under direct observation of the study
team
Endemicity level: 18% to 25%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The treatment group assignment
was performed by random allocation of
numbers 1-4 to the study individuals us-
ing a dBASE IV computer software pro-
gramme.”
Allocation concealment (selection bias) Low risk Quote: “The consignments of drugs were
received at the Danish Bilharziasis Labo-
ratory (DBL), Charlottenlund, Denmark,
where they were coded by a scientist who
was not part of the study team. Coding was
carried out independently for each village.
”
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Unclear risk Quote: “double-blind placebo-controlled
field trial”
Quote: “Ivermectin in 3-mg tablets and
identical placebo were supplied by Merck
&Co., Inc.,USAwhile albendazole in 200-
mg tablets and identical placebo were sup-
plied by SmithKline Beecham. UK.”
Comment: unclear how personnel were
blinded
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Low risk Quote: ”sealed copies of the codes were
kept at DBL until the end of the trial when
they were opened.”
Comment: unclear if codes were revealed
before or after completion of parasitologi-
cal analyses, but we judge assessment of ob-
jective outcomes to be at low risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 82.9% (1181/1425) of ran-
domized participants were evaluated for
primary outcome. Reasons for losses to fol-
low-up were reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No other obvious sources of bias
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Fox 2005
Methods RCT
Study dates: October 1998 to May 1999
Length of follow-up: 6 months
Method of mf assessment/volume of blood: 20 µL-thick smear, fingerprick blood col-
lected between 7.30pm and 9.30pm
Antigen testing: fingerprick blood assessed with Og4C3 ELISA
Method of adverse event assessment: childrenwere questioned and examined at school for
adverse reactions for 7 days. Information was collected on adverse reactions that included
headache, fever, myalgias, abdominal pain, passage of worms in the stool, vomiting,
diarrhoea, cough, and dyspnoea. A treatment impact score was determined for each child
Treatment impact score grading: 1) symptoms were noticed but did not interfere with
daily activities: 2) symptoms caused some interference with daily activities; 3) symptoms
prevented usual daily activities
Participants All children attending any of 12 selected primary schools
Number analysed for primary outcome: 990 participants of 1292 participants random-
ized
Mean age (years): 7.6
Inclusion criteria: 1) an age of 5 - 11 years; 2) anthropometric measurements collected
before and 6 months after treatment; 3) stool specimens collected before and 5 weeks
after treatment; 4) mf smears prepared before and 6 months after treatment; 5) random
assignment to a treatment group
Interventions Single dose
1. Placebo: 2 tablets 250 mg of vitamin C, 318 participants
2. Albendazole: 400 mg plus 1 tablet vitamin C, 328 participants
3. DEC: 6 mg/kg plus 1 tablet vitamin C, 322 participants
4. Albendazole plus DEC: 400 mg plus 6 mg/kg, 324 participants
Outcomes 1. Mf prevalence post-treatment
2. Change in mf prevalence post-treatment
3. Geometric mean mf density and range post-treatment
4. Geometric mean percentage reduction in MF density post-treatment
5. CFA prevalence post-treatment
6. Change in CFA prevalence post-treatment
7. Geometric mean CFA density and range post-treatment
8. Geometric mean percentage reduction in CFA density post-treatment
9. Frequency of specific systemic adverse events post-treatment
10. Treatment impact score for adverse events every day for 7 days post-treatment
Not reported: mean percentage reduction in mf density and CFA density post-treatment
Not included in review: height and weight (anthropometric indices reported as Z-scores)
, stool examination for intestinal helminths
(Note: SDs for geometric mean density changes reported on request by previous review
authors (Addiss 2005)
Notes Study type: school-based
Location: Leogane commune, Haiti
Source of funding: Emerging Infections Program of the Centers for Disease Control
and Prevention and by an Institutional Strengthening Grant from the World Health
Organization to the Hôpital Sainte Croix
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Medication supervised: children took the medication under direct investigator observa-
tion
Endemicity level: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “For each school, all eligible stu-
dents were assigned using a random num-
ber table”
Allocation concealment (selection bias) Low risk Quote: “All laboratory specimens were col-
lected and coded before treatment group
assignment and the code, kept by CDC re-
searchers, was only broken after comple-
tion of sample testing”
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Low risk Quote: “double blind, placebo controlled”.
Comment: although drugs were not iden-
tical, patients likely had no way of identi-
fying them
Quote: “a clinician who was blinded as to
treatment group questioned and examined
the children at school for adverse reactions.
”
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Low risk Quote: “Laboratory personnel, measure-
ment teams, and personnel evaluating stu-
dents for adverse reactions were blinded to
the treatment status of the children.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 76.6% (990/1292) of random-
ized participants were evaluated. Reasons
for losses to follow-up were reported as
due to absence of pretreatment or post-
treatment mf smears required for analy-
sis. Inclusionof all randomizedparticipants
(number evaluable/number randomized):
76.6% (990/1292)
Selective reporting (reporting bias) High risk Comment: prespecified adverse eventswere
not fully reported; abdominal pain, vomit-
ing, diarrhoea anddyspnoeaweremeasured
but not reported
Mean percentage reduction in mf or CFA
density 3 and 6 months after treatment
(efficacy outcome measure 2) were not re-
ported
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Other bias Unclear risk Comment: risk of bias for mf density and
antigen density is unclear, as prior to esti-
mating the percentage reduction between
baseline and follow-up, the authors omit-
ted increases in density. This study simply
provides an assessment of the decrease in
density only in people experiencing a de-
crease. Whilst this rule was applied to both
intervention and control groups, we were
uncertain of the effect of this on the esti-
mate, or exactly what the estimate wasmea-
suring
Gayen 2013
Methods RCT
Study dates: 2006 to 2008
Length of follow-up: 12 months
Method of mf assessment/volume of blood: At pretreatment the method was not stated,
fingerprick blood was collected at night; during treatment and post-treatment it was
membrane filtration, 2 to 3 mL or 8mL venous blood
Method of adverse event (AE) assessment: assessed before and 48 hours after drug ad-
ministration by medical questionnaire. AEs were quantified using a scorecard based on
temperature, blood pressure measurements and questionnaire responses that focused on
rash, fatigue, diarrhoea, appetite changes, vomiting, scrotal pain, headache, myalgias,
cough, and dyspnoea. Scoring was based on a WHO system: mild AE (1); moderate
AE (2); severe AE (3); and life-threatening or disabling AE (4). Scores assigned for all
parameters over all time points for individual participants were added up
Participants Microfilaraemic individuals identified by screening
Number analysed for primary outcome: 32 participants of 32 participants randomized
in the placebo treatment group and albendazole treatment group
Age range/mean age: not reported
Inclusion criteria: asymptomatic mf carriers, aged 18 - 65, > 40 kg, not pregnant or
breastfeeding, and in good health
Exclusion criteria: abnormal hepatic and renal function (SGPT > 60 I.U./L, SGOT > 40
I.U./L, creatinine > 1.4 mg/100 ml), intolerance to treatment drugs, and alcohol abuse
Interventions Multiple doses
1. Placebo: matching placebo for 30 days, 15 participants
2. Albendazole: 400 mg/day (1 tablet) for 7 days, 17 participants
3. Doxycycline: 200 mg (2 capsules of 100 mg) for 30 days, 17 participants
4. Albendazole plus doxycycline: 200 mg doxycycline for 23 days followed by 600
mg doxycycline (200 mg) in combination with albendazole (1 tablet 400 mg) for 7
days, 19 participants
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Gayen 2013 (Continued)
Outcomes 1. Mf prevalence post-treatment
2. Mean mf count post-treatment
3. Change in mean mf count post-treatment (change during treatment and at some
time points post-treatment reported graphically only)
4. Median mf count and range post-treatment
5. Prevalence and scoring of adverse reaction severity post-treatment
Not included in review: change in Wolbachia density post-treatment
Notes Study type: community-based
Location: 2 rural areas in 2 districts of Bankura and Birbhum, West Bengal, India
Source of funding: Department of Biotechnology and the Council of Scientific and
Industrial Research, Ministry of Science and Technology, Government of India
Medication supervised: not reported
Endemicity level: 10.9%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned.. by a trial
monitor who was not associated in the
study”
Sequence generation unclear
Allocation concealment (selection bias) Low risk Quote: “Blinding and coding of drugs was
done by an independent monitor (a scien-
tist who was not an investigator)”
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Low risk Quote: “double-blind: neither the patient
nor the evaluating physician was aware of
the kind of medication that was given.”
Quote: “repacking (drugs) in identical cap-
sules provided by a pharmaceutical com-
pany.”
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 100% (32/32) of randomized
participants in the placebo group and al-
bendazole treatment group were evaluated.
Inclusion of all randomized participants
(number evaluable/number randomized):
100% (32/32)
For adverse reactions, 23.5% (4/17) partic-
ipants in the albendazole group refused to
be evaluated for this outcome, and 100%
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Gayen 2013 (Continued)
(15/15) were evaluated in the placebo
group
Selective reporting (reporting bias) Low risk Comment: prespecified outcomes reported
Mean mf count and percentage reduction
in mean mf count reported graphically for
some time points post-treatment
Other bias High risk Authors reported: “Differences between
treatments were assessed by paired t test us-
ing MS Excel software.”
Comment: This method of analysis is in-
appropriate for comparing differences be-
tween groups, and differences between
treatment groups may be inappropriately
reported
Kshirsagar 2004
Methods RCT
Study dates: October 2000 to November 2003
Length of follow-up: 36 months
Method of mf assessment/volume of blood: thick smear with 60 µL fingerprick or
venepuncture blood, and membrane filtration with 1 mL venepuncture blood, collected
between 9pm and 1am
Antigen testing: ICT
Method of macrofilariae viability assessment: detection of adult filarial worm by ultra-
sound machine; all regions of scrotum and spermatic cord systematically studied, and
FDS identified. Number and location of sites in the scrotal sac were recorded in first
year follow-up. In the second and third year follow-up, individuals were classed ar FDS-
positive or -negative
Method of adverse event assessment: AEs were recorded during the trial, including their
description, frequency, duration, severity and relationship to trial drug i.e. causality
(defined as likely, unlikely, not assessable), and whether it interfered with daily activity.
Safety and tolerability were graded by assessing clinically significant presentation (using
NCI CTC grades) and AEs evaluation based on the description, incidence, severity and
relationship of adverse drug events (using NCI CTC grades) to the drug administration
Participants All individuals living in 2 endemic areas
Number analysed for primary outcome: 139 participants of 1403 participants random-
ized
Mean age (years): 35.5 (DEC); 34.9 (DEC plus albendazole)
Inclusion criteria: The safety study included males and females over 5 years old. The
efficacy study initially included men aged 18 - 50 years old classed as microfilaraemic,
amicrofilaraemic with clinical disease and amicrofilaraemic, asymptomatic. Criteria for
clinical disease were the presence of hydrocoele, lymphoedema and/or lymphadenopathy.
Criteria for inclusion for 12, 24 and 36 month follow-up were participation in the first
efficacy study, and individuals who were microfilaraemic at baseline in the safety study
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Kshirsagar 2004 (Continued)
Exclusion criteria: pregnancy or breast-feeding, history of allergy to DEC or albendazole
(or drugs of that class), treatment with antifilarial drugs in the past year, participation
in a new drug study in the past 6 months, seriously ill, conditions likely to hamper
compliance of the person in the study, inability to take medication orally
Interventions Single dose, given once every year (3 annual treatments in total)
1. DEC: 6 mg/kg plus matching placebo-albendazole, 698 participants
2. Albendazole plus DEC: 400 mg plus 6 mg/kg, 705 participants
Outcomes For participants in the efficacy group:
1. Mf prevalence post-treatment (determined using 2 techniques)
2. Change in mf prevalence post-treatment (determined using 2 techniques)
3. Mean (SD) mf density post-treatment
4. Change in mean mf density post-treatment
5. CFA prevalence post-treatment
6. Change in CFA prevalence post-treatment
7. Adult worm prevalence (determined by ultrasound) post-treatment
8. Change in adult worm prevalence post-treatment
9. Number of participants with adverse drug reactions on days 2 or 5 and
proportion that are ‘likely’
10. Number of participants with adverse events (AEs) that interfered with daily
activities
11. Total number of participants experiencing AEs, AEs that inferred with daily
activity, and AEs that did not interfere with daily activity, after the first, second and
third dose
Note: At the 3-, 6- and 12-month follow-up, results were stratified by male patients
mf-positive at baseline (43 participants), with clinical disease (30 participants), and mf-
negative and asymptomatic (30 participants), and some outcomes were not fully reported
at all follow-up time points. At 12, 24 and 36 months follow-up, additional mf-positive
individuals were analysed, and all individuals were assessed together for each outcome
(excluding ultrasound examination, which included only male participants)
Measured but not reported: number of sites of FDS in each participant pre- and post-
treatment, and the reduction in number of sites of FDS at each time point up to 12
months
For participants in the safety group:
1. Adverse events: total incidence of AEs and total number of participants with
adverse drug reactions on days 2 and 5 (day 5 was cumulative), number of early
terminations, number of participants where adverse events interfered with daily
activities, and global assessment of tolerability (very good or good, satisfactory, poor or
insufficient, not assessable). Severity of adverse reactions was also categorized according
to the National Cancer Institute Common Toxicity Criteria (NCI 1999)
Not included in review: mean and SD plasma concentration of treatment drugs
Notes Study type: community-based
Location: 2 endemic villages in Wardha, Maharashtra (Western India)
Source of funding: UNDP/World bank/WHO Special Program for Research and Train-
ing in Tropical Diseases (TDR)
Medication supervised: “The drug from the assigned bottle... was then given under
supervision”
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Kshirsagar 2004 (Continued)
Endemicity level: 7.27% in 1995
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: states randomized, but random
sequence generation not reported
Allocation concealment (selection bias) Low risk Quote: “Each envelope (independently
packaged by Cipla Limited) contained 10
tablets of DEC and 1 tablet of ALB (or
placebo) according to the randomization
code and was labelled with study allocation
numbers.”
Quote: “The randomization code for each
subject was sealed and kept with TDR, PI,
and clinical monitor.”
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Low risk Quote: “double blind”
Quote: “Tablets of Banocide brand of
DEC (50 mg, GSK, India), ALB (400 mg,
SmithKline Beecham,UK) and matching
placebowere provided through product de-
velopment team of WHO/TDR”
Quote: “The investigating team and par-
ticipants were blinded to the code.”
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Low risk Quote: “Following completion of both the
safety and efficacy study... the data was
locked and sent to the statistician,who then
broke the sealed code and analysed the data
independently.”
Blinding for ultrasound outcome was
specifically reported: “Detection of adult
filarial worm was assessed by USG...
which was carried out by trained personnel
blinded to Mf result, the group to which
patient belonged.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 99.4% (1395/1403) of ran-
domized participants in the safety study
group were evaluated. Reasons for losses
to follow-up were reported. Inclusion of
all randomizedparticipants (number evalu-
able/number randomized): 99.4% (1395/
1403)
For efficacy study group, 7.3% (103/1403)
were included in assessments up to 12
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Kshirsagar 2004 (Continued)
months, and 10% (139/1403) were in-
cluded in assessments at 12 months and
later follow-ups. Incomplete outcome data
were reported at some follow-up time
points up to 12 months, and reasons for in-
complete outcome data were not reported.
Inclusion of all randomized participants
(number evaluable/number randomized):
10% (139/1403)
Selective reporting (reporting bias) High risk Comment: Data were collected for efficacy
outcomes every 3, 6 and 12 months for 3
years, but only the first 3 and 6 months
were reported; annual follow-up data was
presented after 12 months due to “negligi-
ble results”
After the second and third annual dose,
measures of safety and tolerability were not
reported as outlined in the Methods
In addition, the Methods state the number
of sites of FDS in each participant and cal-
culated reduction innumber of sites of FDS
was measured, but this was not reported
Quote: “The secondary efficacy variables
were the time to clear CFA and FDS, and
number of sites of FDS in each patient at
pre-treatment, 6 months and 1 year.. re-
duction in number of sites of FDS at each
time point were also calculated.”
Other bias Low risk No other obvious sources of bias
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Pani 2002
Methods RCT
Study dates: not reported
Length of follow-up: 36 months
Method of mf assessment/volume of blood: membrane filtration, 1 mL venous blood.
Blood samples (2 mL) were collected from mf carriers at different time points during
the night
Antigen testing: ICT and Og4C3 ELISA test kit on 50 µL serum
Method of macrofilariae viability assessment: FDS was assessed in male mf carriers by
ultrasound examination. Both sides of the scrotum were examined serially, and inguinal
lymphatic vessels and lymph nodes and thighs, and the lymphatic vessels and nodes of
axillae and upper arms were also examined
Method of adverse event assessment: participants were monitored for adverse reactions
at 8-hourly intervals for 24 hours, and thereafter every 24 hours for 3 days. All systemic
adverse reactions were recorded by assigning them a score of either 0 (none) or 1 (mild)
or 2 (moderate) or 3 (severe)
Participants Microfilariaemic individuals identified by screening
Number analysed for primary outcome: 54 participants of 54 participants randomized
Mean age (years): 24.67
Inclusion criteria: healthy asymptomatic volunteers (male and female) between 10 and
57 years old who were mf-positive
Exclusion criteria: patients with a history of any drug intolerance, reaction or allergy,
presence of intestinal helminth cysts or ova in stool, history of consuming either alben-
dazole or DEC in the preceding year
Interventions Single dose
1. Albendazole: 400 mg, 19 participants
2. DEC: 6 mg/kg, 17 participants
3. Albendazole plus DEC: same as above, 18 participants
Outcomes 1. Mf prevalence post-treatment
2. Change in mf prevalence post-treatment
3. Change in geometric mean mf density and mean mf density post-treatment
expressed as percentage of pre-therapy geometric mean
4. Change in frequency distribution of parasite density post-treatment
5. CFA prevalence post-treatment
6. Change in CFA prevalence post-treatment
7. CFA mean intensity (and SD) post-treatment
8. Change in CFA mean intensity (and SD) post-treatment
9. Prevalence of FDS post-treatment
10. Incidence and mean score of specific and overall adverse reactions
11. Age- and gender-specific adverse reaction incidence and mean intensity of score
Not included in review: haematological and biochemical parameters
Notes Study type: hospital-based
Location: Pondicherry, India
Source of funding: Indian Council of Medical Research, New Delhi
Medication supervised: “under the direct supervision of the medical team.”
Endemicity level: not reported
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Pani 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated”
Generation of allocation sequence unclear
Allocation concealment (selection bias) Low risk Quote: “Blinding and coding of the drugs
was done by an independent monitor (a se-
nior scientist who was not an investigator)
after repacking in look-alike capsules by a
pharmaceutical company”
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Low risk Described as “double blind”
Quote: “patients, clinicians evaluating the
adverse effects... were unaware of the indi-
vidual therapy schedules.”
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Low risk Quote: “laboratory staff carrying out the
laboratory tests andmeasuringmf and anti-
gen levels, were unaware of the individual
therapy schedules.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 100% (54/54) of randomized
participants were evaluated. No losses to
follow-up were reported. Inclusion of all
randomized participants (number evalu-
able/number randomized): 100% (54/54)
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Low risk The authors reported: “Student’s t-test was
carried out for comparison of mean counts
of mf and mean optical density values
of Og4C3 test results between the drug
groups.”
Comment: Mean optical density values of
Og4C3 test results between groups were
not compared and no statistical output re-
ported; but outcome data were clearly re-
ported
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Rizzo 2007
Methods RCT
Study dates: not reported
Length of follow-up: 12 months
Method of mf assessment/volume of blood: membrane filtration of 1mL venous blood
using Nucleopore filter (3 mm pore size). 5 mL venous blood was collected between
11pm and 1am, and if analysis of 1 mL blood appeared negative for mf, the remaining
blood sample (4 mL) was also checked for mf by membrane filtration
Participants Microfilaraemic individuals identified by screening and stratified by mf density
Number analysed for primary outcome: 82 participants of 84 participants randomized
Age range (years): 9 to 19
Inclusion criteria: aged 9 to 19 years and microfilaraemic
Exclusion criteria: 1) antifilarial treatment in previous 6 months; 2) history of health
conditions for which antifilarial drugs might be contraindicated; 3) pregnant women;
4) personal or parental alcohol or drug abuse; 5) frequently moved within or outside the
Greater Recife area
Interventions Single dose
1. DEC: 6 mg/kg, 43 participants
2. Albendazole plus DEC: 400 mg plus 6 mg/kg, 41 participants
Outcomes 1. Mf prevalence post-treatment
2. Change in mf prevalence post-treatment
3. Geometric mean mf intensity post-treatment
4. Change in geometric mean mf intensity post-treatment
Also reported adverse events: overall incidence of systemic AEs, incidence of localized
AEs, duration of events, proportion experiencing mild and severe events. List of most
common systemic AEs and proportion of participants experiencing them
(Note: CIs and SDs for log mean mf density, and proportion of participants with AEs
in each treatment group were obtained from the authors on request)
Notes Study type: hospital-based
Location: Jaboata~o dos Guararapes, Greater Recife, Brazil
Source of funding: The Amaury Coutinho Non-governmental Organization
Medication supervised: treated under direct supervision
Endemicity level: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A restricted block-randomization
list for each stratum was then generated (by
an individual who was not otherwise con-
nected with the research).”
Allocation concealment (selection bias) High risk Quote: “Patients were allocated, as they
were recruited, to one of the two treatment
arms (by G.D.), according to their baseline
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Rizzo 2007 (Continued)
levels of microfilaraemia.”
Allocation was not concealed, participants
were allocated according to a characteristic
Blinding of participants and personnel
(performance bias)
Laboratory outcome
High risk Open study, no placebo used
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Low risk Quote: “blinded primary evaluation of out-
come (microfilaraemia prevalence and in-
tensity)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 82/84 (97.6%) of randomized
participants were evaluated. Reasons for
losses to follow-up were reported. Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 97.6%
(82/84)
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Low risk No other obvious sources of bias
Simonsen 2004
Methods RCT
Study dates: June 2001 to July 2002
Length of follow-up: 12 months
Method of mf assessment/volume of blood: counting chamber technique, 100 µL fin-
gerprick blood
Antigen testing: CFA quantified by Og4C3 TropBio ELISA kit using fingerprick blood;
blood sampling for mf and CFA started at 9pm
Method of adverse event assessment: children were followed for 5 days post-treatment
by passive observation Adverse reactions and their severity were recorded
Participants All children attending any of 6 selected primary schools
Number analysed for primary outcome: 1221 participants of 1829 participants random-
ized
Age range (years): 6 to 18
Inclusion criteria: standard 1 - 6 pupils
Exclusion criteria: pupils from the highest class as they would not be attending the
schools at the 1-year follow-up surveys
Interventions Single dose
1. Albendazole plus ivermectin: 400 mg plus 150 to 200 µg/kg, 586 participants
2. Ivermectin: 150 to 200 µg/kg plus albendazole-placebo, 635 participants
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Simonsen 2004 (Continued)
Outcomes For mf-positive individuals only:
1. Mf prevalence
2. Change in mf prevalence
3. Geometric mean mf density
4. Change in geometric mean mf density
For CFA-positive individuals only:
1. CFA prevalence
2. Change in CFA prevalence
3. Geometric mean CFA intensity
4. Change in geometric mean CFA intensity
For individuals mf/CFA-negative at baseline:
5. New cases of mf positivity
6. New cases of CFA positivity
Not included in review: specific adverse reactions, such as headache, fever, joint pain,
diarrhoea, dizziness, vomiting and itching and the total number of cases were reported,
but number of events in each treatment group was not reported
Notes Study type: school-based
Location: Tanga and Pangani Districts, Tanzania
Source of funding: Partnership for Child Development and the Danish Bilharziasis
Laboratory
Medication supervised: The tablets were swallowed under direct observation of amember
of the project team
Endemicity level: The school’s catchment area was known to have high endemicity of
lymphatic filariasis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The children were randomized
into two treatment groups by using com-
puter generated random numbers.”
Allocation concealment (selection bias) Low risk Quote: “Before shipment to Tanzania,
the albendazole and albendazole-placebo
tablets were coded (separately for each
school) at the Danish Bilharziasis Labora-
tory by a scientist who was not part of the
study team.”
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Unclear risk Quote: “A randomized double-blind field
trial”
Matching- albendazole placebo was used.
Unclear how personnel blinded
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Simonsen 2004 (Continued)
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 1221/1829 (66.8%) of ran-
domized participants were evaluated. Rea-
sons for losses to follow-up were reported
as due to exclusion of participants from
analyses if they were not present for subse-
quent follow-up examinations. Inclusionof
all randomizedparticipants (number evalu-
able/number randomized): 66.8% (1221/
1829)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias High risk Comment: For mf density, authors re-
ported: “overall reductions being slightly
but statistically significantly higher for the
combination than for ivermectin alone”
However, authors reported statistical anal-
ysis by paired t-test and repeated-measures
ANOVA for correlated samples, and use
of pairwise contrast tests to examine dif-
ferences between groups at specific time
points. The results of pairwise tests for
differences between groups have not been
reported, and use of repeated measures
ANOVA is unsuitable for between-group
comparisons
Wamae 2011
Methods Cluster-RCT
Unit of cluster: household
Method to adjust for clustering: multilevel mixed-effects regression models for some
analyses
Average cluster size: not reported
ICCs: not reported
Study dates: 1998 to 2000
Length of follow-up: 24 months
Method of mf assessment/volume of blood: counting chamber technique, 100 µL fin-
gerprick blood collected between 8.30pm and 12am. Also reported venous samples were
collected
Antigen testing: Og4C3 antigen ELISA
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Wamae 2011 (Continued)
Participants Microfilaraemic households identified by screening
Number analysed for primary outcome: 51 microfilaraemic participants of 108 partici-
pants randomized in theDEC treatment group and theDEC plus albendazole treatment
were analysed for mf density. Unclear how many individuals were included in regression
models
Age range (low and upper quartiles): 12, 40
Inclusion criteria: over 5 years of age and a member of a household where at least 1
member was microfilaraemic
Exclusion criteria: severely ill or pregnant
Interventions Single dose, given once every year (3 annual treatments in total)
1. DEC: 6 mg/kg, 54 participants
2. Albendazole plus DEC: 400 mg plus 6 mg/kg, 54 participants
3. Albendazole: 400 mg, 62 participants
Outcomes Reported:
1. Mean (log) mf density post-treatment (reported graphically for mf-positive
individuals only)
2. Change in mean (log) mf density post-treatment (reported graphically for mf-
positive individuals only)
3. Percentage reduction in geometric mean mf density post-treatment
4. Multilevel mixed-effects regression model analysis of log mf count
5. Mean (log) CFA density post-treatment (reported graphically for CFA-positive
individuals only)
6. Change in mean (log) CFA density post-treatment (reported graphically for CFA-
positive individuals only)
7. Percentage reduction in mean CFA levels post-treatment
8. Multilevel mixed-effects regression model analysis of log CFA levels
Also commented on adverse events.
Not included in review: No data were useable for review. Also reported analyses of
antifilarial IgG1 and IgG4 levels post-treatment
Notes Study type: community-based
Location: Muhaka area in Msambweni district, south coastal Kenya
Source of funding: UNICEF/UNDP/World Bank/WHO Special Programme for Re-
search and Training in Tropical Diseases (TDR)
Medication supervised: not reported
Endemicity level: 15 - 25% mf prevalence and > 35% antigenaemia prevalence
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “64 households were randomly as-
signed to three treatment groups”
Unclear how they were randomized
Allocation concealment (selection bias) Unclear risk Not reported
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Wamae 2011 (Continued)
Blinding of participants and personnel
(performance bias)
Laboratory outcome
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
Laboratory outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 82.9% (170/205) of random-
ized participants in selected households
were treated at baseline. Reasons for exclu-
sions due to absence of blood specimen,
reasons for absence were not reported. Un-
clear if 170 participants treated were fol-
lowed up. Methods state ITT analysis was
done, but unclear if data were imputed for
35 participants that did not receive treat-
ment
64.7% (110/170) of participant samples
were randomly assessed for antigenaemia at
baseline, and53.5%(91/170) sampleswere
assessed post-treatment
Selective reporting (reporting bias) High risk The authors state “Multilevel mixed-effects
regression models were used to compare
changes in log MF... and log CFA with
time between the three treatments”. The
effect of treatment over time (1 week, 6
months, 12 months, 24 months) was re-
ported for mf density only. Effect of treat-
ment on changes in CFA density were re-
ported for 24 month follow-up only (with
statistically significant difference reported
between treatment groups):
Quote: “The model revealed significant re-
duction of MF count with treatment over
time (p <0.001) in all treatment groups and
at all time points... there was greater reduc-
tion in MF count in the DEC/ALB group
compared to the DEC group although the
difference was not statistically significant
(geometric mean difference 2.9, 95% con-
fidence interval 1.5 to 12.9, p = 0.146).”
Quote: “The model revealed significant re-
duction of CFA (p < 0.001) in all treatment
groups at 2 years of follow-up... DEC/
ALB combination treatment was also sig-
nificantly more effective than DEC alone
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Wamae 2011 (Continued)
(geometric mean difference 4.4, 95% con-
fidence interval 0.6-9.67, p = 0.049).”
Other bias High risk Comment:
1. Recruitment bias: low (unlikely to
change households)
2. Loss of clusters: unclear (as stated
above, number analysed is unclear and
number of clusters lost to follow-up is
unknown)
3. Incorrect analysis: high (analyses of
mf and CFA prevalence and density are
not cluster-adjusted)
4. Baseline imbalance: low (no
differences apparent)
5. Compatibility with RCTs
randomized by individual: N/A
Data were not analysed in this review
Abbreviations: (S)AE: (serious) adverse event; ALB: albendazole; CFA: circulating filarial antigen; DEC: diethylcarbamazine; FDS:
filarial dance sign; ITT: intention-to-treat; mf: microfilariae; RCT: randomized controlled trial; SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Debrah 2006 All participants received ivermectin and albendazole 4 months after treatment with either doxycycline or placebo.
This trial did not compare albendazole co-administered with ivermectin to ivermectin for lymphatic filariasis
Dembele 2010 The comparison groups - albendazole plus ivermectin given together at increased dose and frequency versus the
standard dose of albendazole plus ivermectin - do not provide answers to question of whether adding albendazole
to ivermectin improves treatment outcomes
Ismail 1998 The comparison groups - albendazole versus albendazole plus ivermectin versus albendazole plus DEC versus
DEC plus ivermectin - do not match those in the review; these comparisons do not provide answers to the question
of whether adding albendazole to ivermectin or DEC improves outcomes compared to ivermectin or DEC alone
Jayakody 1993 The comparison groups - albendazole versus DEC - did not match those in the review; this does not provide
answers to the question as to whether adding albendazole to DEC improves outcomes compared to DEC alone
Kar 2015 The comparison groups - albendazole plusDEC given together at increased dose and frequency versus the standard
dose of albendazole plus DEC - do not provide answers to the question of whether adding albendazole to DEC
improves treatment outcomes
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(Continued)
King 2018 The comparison groups - albendazole plus DEC given annually versus albendazole plus DEC given once versus
albendazole plus DEC plus ivermectin given once - do not provide answers to the question of whether adding
albendazole to DEC improves treatment outcomes
Makunde 2003 Comparison groups do not match those in review; for single infections with W bancrofti these were albendazole
plus ivermectin versus albendazole alone; for co-infections of W bancrofti and Onchocerca volvulus these were
ivermectin plus albendazole versus placebo
Namwanje 2011 The comparison groups for people with lymphatic filariasis - albendazole plus ivermectin plus praziquantel versus
albendazole plus ivermectin with no praziquantel or praziquantel given after 1 week - do not match those of
the review; this does not provide answers to the question of whether adding albendazole to ivermectin improves
treatment outcomes
Nash 2017 Although the comparison groups - albendazole versus placebo - match those sought by the review, the study did
not include the patient population relevant to the review (participants were not infected by W bancrofti)
Pion 2015 Not an RCT; all individuals were given albendazole in a community study
Shenoy 1999 The comparison groups - albendazole versus albendazole plus ivermectin versus albendazole plus DEC versus
DEC plus ivermectin - do not match those in the review
Shenoy 2002 Study of safety and tolerability of adding albendazole to DEC; carried out only in people without microfilaraemia
(i.e. presumably uninfected)
Tafatatha 2015 The comparison groups - albendazole plus ivermectin given together at increased dose and frequency versus
the standard dose of albendazole plus ivermectin - do not provide answers to the question of whether adding
albendazole to ivermectin improves treatment outcomes
Thomsen 2016 The comparison groups - albendazole plus DEC versus albendazole plus DEC plus ivermectin - do not match
those in the review; this does not provide answers to the question of whether adding albendazole to DEC or
ivermectin improves outcomes compared to DEC or ivermectin alone
Yongyuth 2006 Although the comparison groups - albendazole plus DEC versus DEC - match those sought by the review, the
trial reports were not clear or consistent. In one report the number of participants randomized to each group was
very small, and differential losses to follow-up between treatment groups were reported
Abbreviations: DEC: diethylcarbamazine; RCT: randomized controlled trial.
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Characteristics of studies awaiting assessment [ordered by study ID]
Purkait 2017
Methods RCT
Length of follow-up: 12 months
Method of microfilariae (mf) assessment/volume of blood: not reported
Method of adverse event assessment: not reported
Participants Number analysed: 164 participants
Inclusion criteria: patients with filarial chyluria
Interventions 1. DEC: 6 mg/kg x 12 days, 38 participants
2. Albendazole plus DEC: 400 mg single dose plus 6 mg/kg x 12 days, 40 participants
3. Albendazole plus DEC plus ivermectin: 400 mg single dose plus 6 mg/kg x 12 days plus 200 µg/kg single
dose, 39 participants
4. Albendazole plus DEC plus ivermectin plus doxycycline: 400 mg single dose plus 6 mg/kg x 12 days plus 200
µg/kg single dose plus 200 mg/day x 4 weeks, 39 participants
Outcomes 1. Success rate of treating filarial chyluria
2. Recurrence of filarial chyluria
3. Number of cases reporting adverse events
Notes Conference abstract
Corresponding authors contacted: purkaitbimalesh1@gmail.com; drashokkumarsokhal@gmail.com
Study type: not reported
Location: not reported
Sources of funding: not reported
Medication supervised: not reported
Endemicity level: not reported
Abbreviations: DEC: diethylcarbamazine; mf: microfilariae; RCT: randomized controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Albendazole alone or added to a microfilaricidal drug
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfilaraemia (mf) prevalence:
longest follow-up (up to 12
months)
12 5027 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.85, 1.07]
1.1 Albendazole versus
placebo
4 1406 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.81, 1.19]
1.2 Albendazole plus DEC
versus DEC
7 1102 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.75, 1.09]
1.3 Albendazole plus
ivermectin versus ivermectin
4 2519 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.80, 1.19]
2 Antigenaemia prevalence:
longest follow-up (up to 12
months)
7 3774 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.97, 1.12]
2.1 Albendazole versus
placebo
2 1054 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.91, 1.25]
2.2 Albendazole plus DEC
versus DEC
5 954 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.14]
2.3 Albendazole plus
ivermectin versus ivermectin
2 1766 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.94, 1.16]
3 Adult worm prevalence by
ultrasound: longest follow-up
(up to 12 months)
3 165 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.72, 1.86]
3.1 Albendazole plus DEC
versus DEC
3 165 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.72, 1.86]
4 New clinical disease (new cases
hydrocoele)
1 535 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.23, 8.36]
4.1 Albendazole versus
placebo
1 255 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.45]
4.2 Albendazole plus
ivermectin versus ivermectin
1 280 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [0.17, 19.73]
5 Pre-existing clinical disease (net
improvement)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Albendazole versus
placebo
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Albendazole plus
ivermectin versus ivermectin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events 6 2894 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.84, 1.13]
6.1 Albendazole versus
placebo
2 678 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.61, 1.48]
6.2 Albendazole plus DEC
versus DEC
4 1589 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.79, 1.11]
6.3 Albendazole plus
ivermectin versus ivermectin
1 627 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.77, 1.74]
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Comparison 2. Albendazole versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfilaraemia (mf) prevalence:
longest follow-up (up to 12
months)
4 1406 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.81, 1.19]
2 Microfilaraemia (mf) prevalence:
stratified by baseline infection
(up to 6 months follow-up)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 All mf positive at baseline 3 175 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.90, 1.10]
2.2 Infected and uninfected
individuals at baseline
2 783 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.73, 1.43]
3 Microfilaraemia (mf) prevalence:
stratified by baseline infection
(12 months follow-up)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 All mf positive at baseline 2 169 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.86, 1.03]
3.2 Infected and uninfected
individuals at baseline
1 591 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.71, 1.26]
4 Antigenaemia prevalence:
longest follow-up (up to 12
months)
2 1054 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.91, 1.25]
5 Antigenaemia prevalence:
stratified by baseline infection
(6 months follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Infected and uninfected
individuals at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Antigenaemia prevalence:
stratified by baseline infection
(12 months follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 All adult worm positive
(CFA) at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Infected and uninfected
individuals at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Clinical disease 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 New cases hydrocoele 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Net improvement
(lymphoedema)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Total improvement
(hydrocoele)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Adverse events 2 678 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.61, 1.48]
77Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Comparison 3. Albendazole plus DEC versus DEC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfilaraemia (mf) prevalence:
longest follow-up (up to 12
months)
7 1102 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.75, 1.09]
2 Microfilaraemia (mf) prevalence:
stratified by baseline infection
(up to 6 months follow-up)
7 1004 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.70, 1.08]
2.1 All mf positive at baseline 4 224 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.57, 1.21]
2.2 All adult worm positive
(CFA or ultrasound) at baseline
2 289 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.74, 1.18]
2.3 Infected and uninfected
individuals at baseline
1 491 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.32, 1.21]
3 Microfilaraemia (mf) prevalence:
stratified by baseline infection
(12 months follow-up)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 All mf positive at baseline 4 224 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.54, 1.45]
3.2 All adult worm positive
(CFA or ultrasound) at baseline
2 291 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.27]
3.3 Infected and uninfected
individuals at baseline
1 139 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.78, 1.82]
4 Microfilaraemia (mf) prevalence:
stratified by baseline infection
(24 months follow-up)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 All mf positive at baseline 1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.06, 13.93]
4.2 All adult worm positive
(CFA) at baseline
1 245 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.46, 1.17]
4.3 Infected and uninfected
individuals at baseline
2 868 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.71, 1.27]
5 Microfilaraemia (mf) prevalence:
stratified by baseline infection
(36 months follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Infected and uninfected
individuals at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Antigenaemia prevalence:
longest follow-up (up to 12
months)
5 954 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.14]
7 Antigenaemia prevalence:
stratified by baseline infection
(6 months follow-up)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 All mf positive at baseline 1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.38, 1.11]
7.2 All adult worm positive
(CFA) at baseline
2 287 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.95, 1.04]
7.3 Infected and uninfected
individuals at baseline
2 590 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.84, 1.27]
8 Antigenaemia prevalence:
stratified by baseline infection
(12 months follow-up)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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8.1 All mf positive at baseline 1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.22, 4.05]
8.2 All adult worm positive
(CFA) at baseline
3 332 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.92, 1.10]
8.3 Infected and uninfected
individuals at baseline
1 139 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.83, 1.34]
9 Antigenaemia prevalence:
stratified by baseline infection
(24 months follow-up)
3 445 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.96, 1.27]
9.1 All mf positive at baseline 1 35 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.91, 1.24]
9.2 Infected and uninfected
individuals at baseline
2 410 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.95, 1.30]
10 Antigenaemia prevalence:
stratified by baseline infection
(36 months follow-up)
2 174 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.92, 1.42]
10.1 All mf positive at baseline 1 35 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.95, 1.53]
10.2 Infected and uninfected
individuals at baseline
1 139 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.84, 1.50]
11 Adult worm prevalence by
ultrasound: longest follow-up
(up to 12 months)
3 165 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.72, 1.86]
12 Adult worm prevalence by
ultrasound: stratified by
baseline infection (6 month
follow-up)
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
12.1 All mf positive at baseline 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 All adult worm positive
(ultrasound) at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 Infected and uninfected
individuals at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Adult worm prevalence by
ultrasound: stratified by
baseline infection (12 month
follow-up)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 All mf positive at baseline 2 57 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.37, 1.66]
13.2 All adult worm positive
(ultrasound) at baseline
1 46 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.69, 3.40]
13.3 Infected and uninfected
individuals at baseline
1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.53, 1.75]
14 Adult worm prevalence by
ultrasound: stratified by
baseline infection (24 month
follow-up)
2 118 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.62, 2.79]
14.1 All mf positive at baseline 1 16 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [0.09, 40.60]
14.2 Infected and uninfected
individuals at baseline
1 102 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.59, 2.77]
15 Adverse events 4 1589 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.79, 1.11]
16 Adverse events: stratified by
type
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Any 4 1589 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.79, 1.11]
16.2 Interferred with daily
activity
2 1478 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.67, 1.77]
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16.3 Localized 1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.43]
Comparison 4. Albendazole plus ivermectin versus ivermectin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microfilaraemia (mf) prevalence:
longest follow-up (up to 12
months)
4 2519 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.54, 1.31]
2 Microfilaraemia (mf) prevalence:
stratified by baseline infection
(up to 6 months follow-up)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 All mf positive at baseline 4 607 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.50, 1.02]
2.2 Infected and uninfected
individuals at baseline
3 1929 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.23, 1.25]
3 Microfilaraemia (mf) prevalence:
stratified by baseline infection
(12 months follow-up)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 All mf positive at baseline 2 348 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.88, 1.12]
3.2 Infected and uninfected
individuals at baseline
2 1811 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.88, 1.33]
4 Antigenaemia prevalence:
longest follow-up (up to 12
months)
2 1766 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.94, 1.16]
5 Antigenaemia prevalence:
stratified by baseline infection
(6 months follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 All adult worm positive
(CFA) at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Infected and uninfected
individuals at baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Antigenaemia prevalence:
stratified by baseline infection
(12 months follow-up)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 All adult worm positive
(CFA) at baseline
2 733 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.98, 1.08]
6.2 Infected and uninfected
individuals at baseline
2 1766 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.94, 1.16]
7 Clinical disease 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 New cases hydrocoele 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Net improvement
(lymphoedema)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Net improvement
(hydrocoele)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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A D D I T I O N A L T A B L E S
Table 1. Mass drug administration (MDA) programmes for filariasis
Endemic for Drug recommendation
Lymphatic
filariasis
Onchocerciasis Loiasis Albendazole Ivermectin Diethylcarbamazine Regimen
+ + +a Yes No No Twice per yearb,c
+ + - Yes Yes No Annualb
+ - +a Yes No No Twice per yearb,c
- + + No Yes No Annualc
+d - - Yes No Yes Annualb
- + - No Yes No Annual
- - + No No No -
aIn areas where L loa is endemic, ivermectin must be used with caution as people with high L loa microfilaraemia are at greater risk of
experiencing serious adverse effects (SAEs). Albendazole alone given twice per year is recommended when mass drug administration
with ivermectin has not yet occurred. Where mass drug administration with ivermectin has already occurred for either lymphatic
filariasis or onchocerciasis, ivermectin distribution can continue under current guidance on the use of ivermectin for onchocerciasis
in areas co-endemic for loiasis. For further information, see reference c.
bWHO 2017a
cMectizan Expert Committee 2004
dAnnual treatment with the triple-drug therapy of ivermectin, DEC and albendazole is recommended in specified settings.
Table 2. Parasitaemia density data: reported statistical analysis
Study details Reported statistical analysis
Trial Type of peo-
ple enrolled
Mf den-
sity outcome
denominator
CFA density
outcome de-
nominator
Mean
reported
Explicit
about
method used
to accommo-
date peo-
ple with zero
counts
Explicit
about
method
used to calcu-
late % reduc-
tion in den-
sity
If density in-
creased post-
treatment,
authors
set change to
zero
Beach 1999 Infected and
uninfected
All mf-
positive
NA GM No Yes Yes
Bockarie 2007 Infected and
uninfected
All CFA-posi-
tivea
All CFA-posi-
tiveb
GM Yes
(“n+1”)
Noa NRa
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Table 2. Parasitaemia density data: reported statistical analysis (Continued)
De Britto
2015
All mf-
positive
All mf-
positive
All CFA-posi-
tive
LM No NR NA
Dreyer 2006 All FDS-posi-
tive
All individuals NA GM Noc Noc NRc
Dunyo 2000 Infected and
uninfected
All mf-
positived
All CFA-posi-
tived
GM Yes
Calculation
provided
Noe NRe
Fox 2005 Infected and
uninfected
All mf-
positive
All CFA-posi-
tive
GM Yes
(“n+1”)
Yes Yes
Gayen 2013 All mf-
positive
All mf-
positive
NA AM NA Noe NRe
Kshirsagar
2004
Infected and
uninfected
All mf-
positive
NA AM NAf Noe NRe
Pani 2002 All mf-
positive
All mf-
positive
All individuals GM and AM Nog No NR
Rizzo 2007 All mf-
positive
All mf-
positive
NA GM Yes
(“n+1”)
NR NA
Simonsen
2004
Infected and
uninfected
All mf-
positive
All CFA-posi-
tive
GM Yes
Calculation
provided
Noe NRe
Abbreviations: AM: arithmetic mean; CFA: circulating filarial antigen; FDS: filarial dance sign; GM: geometric mean; LM: log mean;
Mf: microfilariae; NA: not applicable; NR: not reported.
aMf density and percentage reduction in density were reported for all participants irrespective of their pre-treatment infection status
only at the 24-month follow-up. Details were not provided in the Methods, but the standard percentage change calculation was used.
bAntigen density was reported as number of antigenaemic participants with high antigenaemia decreasing to low or to negative, and
number with low antigenaemia converting to negative only at 24-month follow-up.
cAuthors provided further details on request; for mf density the “n+1” formula before log transforming values was used, and% reduction
was calculated using method reported in Addiss 1993.
dAuthors also reported mf and CFA unit geometric mean densities for individuals who were negative for the markers at baseline and
positive at 12 months; however, the change or reduction in population mf or CFA densities for all enrolled individuals was not reported.
eDetails were not provided in the Methods, but the standard percentage change calculation was used.
fAuthors used the arithmetic mean and only assessed participants who remained mf-positive at follow-ups; participants who had
previously been mf-positive but converted to negative were excluded from density calculations.
gThe last version of this review, Addiss 2005, reported further details were provided by Pani 2002 on request; this trial calculated a
William’s mean (a modified geometric mean to take into account zero counts).
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Table 3. Microfilarial density: up to 6 months follow-up
Back-
ground
drug
Risk of
bias: anal-
ysis used
Trial (fol-
low-up)
Intervention (albenda-
zole)
Control Difference between groups post-
treatment
Partici-
pants
Baseline
to follow-
up (% re-
duction)
Partici-
pants
Baseline
to follow-
up (% re-
duction)
% reduc-
tion
Signifi-
cance test-
ing (% re-
duction)
Signifi-
cance test-
ing: mf
density
Placebo Low or un-
clear risk
Dunyo
2000
a,b,c,d
(6 months)
62 1783
(95%
CI 1215 to
2617) to
693 (95%
CI 335 to
1431)
(61.1%)
57 2277
(95%
CI 1576 to
3289) to
2745
(95%
CI 1505 to
5007)
(20.6% in-
crease)
81.7% NR NR
High risk Beach
1999a,d,e
(4 months)
29 14.1 to 5.1
(28.7%)
29 9.3 to 5.3
(17.2%)
11.5% NS (P > 0.
05)
NS (P > 0.
05)
Fox 2005
a,d,e
(6 months)
42 12.1 (95%
CI 10.3 to
14.2) to 4.
4 (95% CI
3.7 to 5.3)
(34.7%)
34 17.
3 (95% CI
14.5 to 20.
6) to 11.2
(95%CI 9.
2 to 13.7)
(10.3%)
24.4% * (P<0.05) * (P <0.05)
Gayen
2013a,f,g
(4 months)
17 3942.32 to
821.88
(79%)
15 4460.7 to
4390.7
(1.6%)
77.4% NRh NR
DEC Low or un-
clear risk
Pani 2002
a,d,f
(6 months)
18 79.4, post-
treatment
NR
(81%)
17 81.3, post-
treatment
NR
(74.7%)
6.3% NR NS (P > 0.
05)
Dreyer
2006d,f
(1 month)
21 55.9 to 12.
7
(53.5%)
23 129.5 to
18.8
(67.1%)
−13.6% NS (P = 0.
24)
NS (P = 0.
83)
Rizzo
2007a,d,f
(6 months)
41 232.6 to
17.7
(92.4%)
[2.36
43 182.6 to
10.5
(94.2%)
−1.8% NR NS (P > 0.
05)
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Table 3. Microfilarial density: up to 6 months follow-up (Continued)
(95%CI 2.
16 to 2.
57) to 1.27
(95%CI 0.
94 to 1.60)
]i
[2.26
(95%CI 2.
04 to 2.
49) to 1.09
(95%CI 0.
74 to 1.43)
]i
Bockarie
2007d,f
(6 months)
126 25.4 to 4.
46
(82.4%)
119 24.4 to 7.
49
(69.3%)
13.1% NR NS (P = 0.
21)
De Britto
2015a,f,j
(6 months)
36 2.26 (± 0.
57) to 0.15
(± NR)
(99.2%)
35 2.22 (± 0.
52) to 0.83
(± NR)
(96%)
3.2% NR NR
High risk Fox 2005
a,d,e
(6 months)
41 13.4 (95%
CI 11.4 to
15.8) to 0.
76
(95%CI 0.
7 to 0.9)
(80.4%)
39 12.9 (95%
CI 11.0 to
15.2) to 2.
8 (95% CI
2.3 to 3.4)
(50.4%)
30% * (P=0.02) * (P <0.05)
Ivermectin Low or un-
clear risk
Dunyo
2000
a,b,c,d
(6 months)
62 1585
(95%
CI 1069 to
2350) to
110 (95%
CI 50 to
239)
(93.1%)
55 2055
(95%
CI 1389 to
3041) to
204 (95%
CI 91 to
451)
(90.1%)
3% NS (P = 0.
71)
NR
Simonsen
2004a,b,d
(6 months)
105 812.6 to
29.8
(96.3%)
98 763.5 to
150
(80.4%)
15.9% NRk NRk
High risk Beach
1999a,d,e
(4 months)
24 13.7 to 0.3
(98.9%)
28 15.5 to 1.5
(76.1%)
22.8% *** (P < 0.
001)
* (P <0.05)
Microfilariae (mf) density data and significance testing for differences between groups at baseline and follow-up, as reported by study
authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the
difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies
used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical
issues.
Abbreviations: CI: confidence interval; mf: microfilariae; NR: not reported; NS: not significant; * (P < 0.05): significant; *** (P <
0.001): significant; ±: standard deviation.
aOnly participants positive for mf at baseline.
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bMeasured in 100 µL blood using counting chamber, and expressed as mf/mL.
cOnly in those individuals with over 100 mf/mL blood before treatment.
dReported as geometric mean.
eMeasured in 20 µL thick smear.
fMeasured in 1 mL blood by membrane filtration, and expressed as mf/mL.
gReported as arithmetic mean.
hAuthors reported “a significant difference between the control and the treated groups (P < 0.05)” using paired t-test for analysis;
however, this statistical test is inappropriate for comparing different groups.
iData within square brackets [ ] indicates log mean intensity data and CIs provided by authors of Rizzo 2007.
jReported as log mean.
kAuthors reported statistical analysis by paired t-test and repeated-measures ANOVA for correlated samples, and use of pairwise contrast
tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear
to be reported.
Table 4. Microfilarial density: 12 months follow-up
Back-
ground
drug
Risk of
bias: anal-
ysis used
Trial Intervention (albenda-
zole)
Control Difference between groups post-
treatment
Partici-
pants
Baseline
to follow-
up (% re-
duction)
Partici-
pants
Baseline
to follow-
up (% re-
duction)
% reduc-
tion
Signifi-
cance test-
ing: % re-
duction
Signifi-
cance test-
ing: mf
density
Placebo Low or un-
clear risk
Dunyo
2000a,b,c
71 798 to 251
(68.5%)
66 971 to 845
(13%)
55.5% NR NS (P = 0.
10)
High risk Gayen
2013a,d,e
17 3942.32 to
432.64
(89%)
15 4460.7 to
4245
(4.8%)
84.2% NRf NR
DEC Low or un-
clear risk
Pani 2002
a,c,d
18 79.4, post-
treatment
NR
(95.4%)
17 81.3, post-
treatment
NR
(89.6%)
5.8% NR NS (P > 0.
05)
Dreyer
2006c,d
22 55.9 to 6.1
(69.5%)
25 129.5 to 4.
8
(85.3%)
−15.8% NS (P = 0.
21)
NS (P = 0.
87)
Rizzo
2007a,c,d
41 232.6 to 5.
2
(97.8%)
[2.36
(95%CI 2.
16 to 2.
57) to 0.74
(95%CI 0.
44 to 1.03)
43 182.6 to 3.
6
(98%)
[2.26
(95%CI 2.
04 to 2.
49) to 0.65
(95%CI 0.
35 to 0.95)
−0.2% NR NS (P > 0.
05)
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Table 4. Microfilarial density: 12 months follow-up (Continued)
]g ]g
Bockarie
2007c,d
126 25.4 to 3.
47
(86.3%)
119 24.4 to 4.
27
(82.5%)
3.8% NR NS (P = 0.
6)
De Britto
2015a,d,h
36 2.26 (± 0.
57) to 0.07
(± NR)
(99.4%)
35 2.22 (± 0.
52) to 0.52
(± NR)
(98%)
1.4% NR NR
High risk Kshirsagar
2004a,d,e
29 NRto249.
2 (± 276.1)
(NR)
24 NRto245.
9 (± 314.8)
(NR)
NR NR NR
Ivermectin Low or un-
clear risk
Dunyo
2000a,b,c
75 614 to 78
(87.3%)
70 640 to 124
(80.6%)
6.7% NR NS (P = 0.
80)
Simonsen
2004a,b,c
105 812.6 to
59.4
(92.7%)
98 763.5 to
124.9
(83.6%)
9.1% NRi NRi
Microfilariae (mf) density data and significance testing for differences between groups at baseline and follow-up, as reported by study
authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the
difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies
used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical
issues.
Abbreviations: mf: microfilariae; NR: not reported; NS: not significant; ±: standard deviation; CI: confidence interval.
aOnly participants positive for mf at baseline.
bMeasured in 100 µL blood using counting chamber, and expressed as mf/mL.
cReported as geometric mean.
dMeasured in 1 mL blood by membrane filtration, and expressed as mf/mL.
eReported as arithmetic mean.
fAuthors reported “a significant difference between the control and the treated groups (P < 0.05)” using paired t-test for analysis;
however, this statistical test is inappropriate for comparing different groups.
gData within square brackets [ ] indicates log mean intensity data and CIs provided by authors of Rizzo 2007.
hReported as log mean.
iAuthors reported statistical analysis by paired t-test and repeated-measures ANOVA for correlated samples, and use of pairwise contrast
tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear
to be reported.
Table 5. Antigen density: longest follow-up (up to 12 months)
Back-
ground
drug
Risk of
bias: anal-
ysis used
Trial
(follow-
up)
Intervention (albenda-
zole)
Control Difference between groups post-
treatment
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Table 5. Antigen density: longest follow-up (up to 12 months) (Continued)
Partici-
pants
Baseline
to follow-
up (% re-
duction)
Partici-
pants
Baseline
to follow-
up (% re-
duction)
% reduc-
tion
Signifi-
cance test-
ing: % re-
duction
Signifi-
cance test-
ing: CFA
density
Placebo Low or un-
clear risk
Dunyo
2000a,b
(12
months)
105 1370 to
1139
(16.9%)
103 1869 to
2757
(47.5% in-
crease)
64.4% NR NS (P = 0.
11)
High risk Fox 2005
a,c
(6 months)
89 2640
(95%
CI 2279 to
3058) to
2428
(95%
CI 2071 to
2847)
(3.2%)
74 2298
(95%
CI 1951 to
2706) to
2479
(95%
CI 2105 to
2919)
(1.7%)
1.5% NS (P > 0.
05)
NS (P > 0.
05)
DEC Low or un-
clear risk
De Britto
2015a,d
(12
months)
36 3.88 (± 0.
48) to 2.
89 (± NR)
(89.8%)
35 3.58 (± 0.
69) to 2.
9 (± NR)
(79.1%)
10.7% NR NS (P = 0.
750)
High risk Fox 2005
a,c
(6 months)
85 2116
(95%
CI 1798 to
2490) to
1350
(95%
CI 1176 to
1549)
(26.7%)
79 2194
(95%
CI 1842 to
2613) to
1597
(95%
CI 1375 to
1855)
(17%)
9.7% NS (P > 0.
05)
NS (P > 0.
05)
Pani 2002e
(12
months)
18 0.47 (± 0.
18) to 0.
08 (± 0.15)
(83%)
17 0.39 (± 0.
21) to 0.
07 (± 0.15)
(82.1%)
0.9% NR NR
Ivermectin Low or un-
clear risk
Dunyo
2000a,b
(12
months)
121 1404 to
834
(40.6%)
99 1689 to
1187
(29.7%)
10.9% NR NS (P = 0.
80)
Simonsen
2004a,b
(12
months)
247 1338.4 to
986.6
(26.3%)
266 1026.3 to
931.6
(9.2%)
17.1% NRf NRf
87Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Circulating filarial antigen (CFA) density data and significance testing for differences between groups at baseline and follow-up, as
reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized),
and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high
when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no
obvious analytical issues.
Abbreviations: CFA: circulating filarial antigen; CI: confidence interval; DEC: diethylcarbamazine; mf: microfilariae; NR: not reported;
NS: not significant; ±: standard deviation.
aOnly participants positive for CFA at baseline.
bMeasured in fingerprick blood, expressed as CFA unit geometric mean intensity.
cMeasured in fingerprick blood, expressed as geometric mean CFA units/mL.
dVolume of blood not reported, expressed as log mean CFA units.
eMeasured in 50 µL blood, expressed as arithmetic mean CFA optical density value.
fAuthors reported statistical analysis by paired t-test and repeated-measures ANOVA for correlated samples, and use of pairwise contrast
tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear
to be reported.
Table 6. Microfilarial density: 24 months and 36 months follow-up
Back-
ground
drug
Risk of
bias:
Analysis
used
Trial
(follow-
up)
Intervention (albenda-
zole)
Control Difference between groups post-
treatment
Partici-
pants
Baseline
to follow-
up (% re-
duction)
Partici-
pants
Baseline
to follow-
up (% re-
duction)
% reduc-
tion
Signifi-
cance test-
ing: % re-
duction
Signifi-
cance test-
ing: mf
density
DEC Low or un-
clear risk
Bockarie
2007a,b
(24
months)c
348 NR to 0.5
(83.7%)
381 NR to 0.7
(87.5%)
−3.8% NR NS (P = 0.
53)
High risk Pani 2002
d,e
(24
months)c
18 98
(± 57) to 0.
52 (± NR)
(99.5%)
17 133 (±
157) to 0.
94 (± NR)
(99.3%)
0.2% NR NS (P > 0.
05)
Kshirsagar
2004d,e
(24
months)f
16 NRto109.
5 (± 143.3)
(NR)
15 NRto99.5
(± 119.3)
(NR)
NR NR NR
Pani 2002
d,e
(36
months)c
18 98 (± 57)
to 0
(100%)
17 133 (±
157) to 0
(100%)
0% NR NR
Kshirsagar
2004d,e
4 NRto57.6
(± 56.0)
8 NR to60.3
(± 61.5)
NR NR NR
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Table 6. Microfilarial density: 24 months and 36 months follow-up (Continued)
(36
months)g
(NR) (NR)
Microfilariae (mf) density (mf/mL) data and significance testing for differences between groups at baseline and follow-up, as reported
by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also
the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when
studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious
analytical issues.
Abbreviations: DEC: diethylcarbamazine; mf: microfilariae; NR: not reported; NS: not significant; ±: standard deviation.
aAll evaluable participants irrespective of baseline mf status.
bReported as geometric mean.
cAfter one annual dose albendazole plus DEC and DEC provided.
dOnly participants positive for mf at baseline.
eReported as arithmetic mean.
fAfter two annual doses albendazole plus DEC and DEC provided.
gAfter three annual doses albendazole plus DEC and DEC provided.
Table 7. Antigen density: 24 months and 36 months follow-up
Back-
ground
drug
Risk of
bias: anal-
ysis used
Trial (fol-
low-up)
Intervention (albenda-
zole)
Control Difference between groups post-
treatment
Partici-
pants
Baseline
to follow-
up (% re-
duction)
Partici-
pants
Baseline
to follow-
up (% re-
duction)
% reduc-
tion
Signifi-
cance test-
ing: % re-
duction
Signifi-
cance test-
ing: CFA
density
DEC High risk Pani 2002
a,b
(24
months)
18 0.5 to 0.48
(4%)
17 0.39 to 0.
44
(12.8% in-
crease)
16.8% NR NR
Pani 2002
a,b
(36
months)
18 0.5 to 1.2
(140% in-
crease)
17 0.39 to 0.
79
(102.6%
increase)
−37.4% NR NR
Circulating filarial antigen (CFA) density data and significance testing for differences between groups at baseline and follow-up, as
reported by study authors. Data was reported as the arithmetic mean and presented by the authors in graphs only; we extracted this
information using WebPlotDigitizer software. We calculated the percentage reduction after treatment, and the difference between
the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical
methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues.
Abbreviations: CFA: circulating filarial antigen; DEC: diethylcarbamazine; mf: microfilariae; NR: not reported.
aOnly participants positive for mf at baseline.
bVolume of blood not reported, expressed as arithmetic mean CFA optical density value.
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WH A T ’ S N E W
Date Event Description
8 January 2019 New citation required and conclusions have changed We performed a search update and included 13 trials in
total. We assessed the certainty of the evidence using the
GRADE approach
8 January 2019 New search has been performed New author team; search update; all data re-extracted; den-
sity data summarizedmore comprehensively; ‘Summary of
findings’ tables constructed
H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 1, 2004
Date Event Description
5 August 2008 Amended Converted to new review format with minor editing.
14 August 2005 New search has been performed The first review update, published in Issue 4, 2005, includes three new trials,
Fox 2005, Kshirsagar 2004, and Simonsen 2004, and a two-year update of
results from the Pani 2002 trial.
C O N T R I B U T I O N S O F A U T H O R S
CM updated the protocol, assessed studies for inclusion, extracted data, assessed the risk of bias in included trials, assessed the certainty
of the evidence, conducted data analysis, and wrote the first draft of the review.
SB assessed studies for inclusion, extracted data, and assessed the risk of bias in included trials.
SJ assessed risk of bias and the certainty of the evidence, and contributed to the data analysis and drafting the final review.
MR helped with the analyses and provided statistical input.
PG provided advice at all stages of the review production, helped with the analyses, and edited the review.
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Differences between review and review update
2018 update: author team changed; we modified the review title from the original title of ‘Albendazole for lymphatic filariasis’ and
updated the entire review.
Following our prespecified protocol update modifications approved by the editorial team, we removed two comparisons (albendazole
versus ivermectin and albendazole versus DEC). We added a new comparison as our main analysis, albendazole alone or added to a
microfilaricidal drug versus placebo or a single microfilaricidal drug. We conducted a new search and added new trials; we excluded
one trial (Jayakody 1993) as it no longer met the inclusion criteria due to the removal of a comparison (albendazole versus DEC).
We could not locate a record that was linked to the Pani 2002 study in the last review version, or the Dahoma record included in
the previous edition’s Characteristics of ongoing studies. After consulting the original review team, Mark Bradley (listed under contact
information) and other researchers, we obtained the Dahoma 2000 record included in this update through David Addiss.
We adopted the latest synthesis methods, including the Cochrane ‘Risk of bias’ tool (Higgins 2011), used GRADE profiler (GRADEpro
2015) to grade the certainty of the evidence, and included ‘Summary of findings’ tables. As we still could not meta-analyse the parasite
density data in this update, we produced additional tables for density outcomes in order to conduct an analysis.
We included a table detailing the reported statistical analysis of density data by trial authors. We changed the structure of the meta-
analyses, where previously the data were analysed by infected participants or all participants (infected and uninfected) separately, our
main analyses assessed all randomized individuals by the longest follow-up up to 12 months. We provided additional analyses by
time point, stratified by whether individuals were infected or both uninfected and infected. We removed the Appendices containing
information that could not be meta-analysed; these remain available in the previous edition (Addiss 2005). We added an Appendix 2
including primary and secondary outcomes from a new cluster-RCT (Wamae 2011) that could not be combined with RCTs.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Albendazole [∗therapeutic use]; Diethylcarbamazine [therapeutic use]; Drug Therapy, Combination; Elephantiasis, Filarial [∗drug
therapy]; Filaricides [∗therapeutic use]; Ivermectin [therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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